[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 303
1. Bapat S, Umranikar S, Satav V, Bapat A, Joshi A, Ranade G: Comparison of fluid absorption during transurethral resection of prostate and Holmium-Yag laser enucleation of benign adenoma of prostate using breath ethanol concentration. Indian J Urol; 2007 Apr;23(2):126-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of fluid absorption during transurethral resection of prostate and Holmium-Yag laser enucleation of benign adenoma of prostate using breath ethanol concentration.
  • OBJECTIVE: We conducted a study to detect, quantify and compare irrigation fluid absorption in transurethral resection of the prostate (TURP) and Holmium laser enucleation of the prostate (HoLEP), using BEC.
  • MATERIALS AND METHODS: The study included 50 patients of lower urinary tract symptoms, secondary to benign enlargement of prostate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1989 Feb;141(2):243-7 [2643719.001]
  • [Cites] Acta Anaesthesiol Scand. 1989 Feb;33(2):146-51 [2922983.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(4):245-51 [3101171.001]
  • [Cites] Int Urol Nephrol. 1987;19(2):165-9 [3667130.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(1):19-26 [3704567.001]
  • [Cites] J Urol. 1969 Dec;102(6):714-9 [4906205.001]
  • [Cites] Br J Urol. 1980 Dec;52(6):526-8 [6161668.001]
  • [Cites] Eur Urol. 1984;10(3):183-6 [6723737.001]
  • [Cites] Lasers Surg Med. 1994;14(3):258-68 [8208052.001]
  • [Cites] Lasers Surg Med. 1996;18(3):278-93 [8778524.001]
  • [Cites] J Endourol. 1998 Jun;12(3):279-82 [9658303.001]
  • [Cites] J Endourol. 1999 Apr;13(3):181-90 [10360498.001]
  • [Cites] J Urol. 1999 Nov;162(5):1640-4 [10524887.001]
  • [Cites] BJU Int. 2000 Jul;86(1):43-6 [10886081.001]
  • [Cites] J Urol. 1958 Mar;79(3):490-9 [13514908.001]
  • [Cites] Surg Clin North Am. 1992 Jun;72(3):531-58 [1589829.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):390-3 [1933159.001]
  • [Cites] J Urol. 1947 Aug;58(2):125-31 [20256856.001]
  • [Cites] Scand J Urol Nephrol. 1986;20(1):9-17 [2422743.001]
  • (PMID = 19675787.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721519
  • [Keywords] NOTNLM ; Breath ethanol concentration / Holmium laser enucleation of the prostate / fluid absorption / transurethral resection of the prostate
  •  go-up   go-down


2. Barrier F, de La Guerenne A, Semjen E, Wierre L, Horrent S, Decaudin B, Resibois JP, Weillaert MP, Azar R, Odou P: [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma]. Ann Biol Clin (Paris); 2006 Jul-Aug;64(4):347-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneously acquired haemophilia: report of a patient with prostatic adenoma].
  • [Transliterated title] Hémophilie A acquise secondaire à un adénome prostatique.
  • Two diagnosis were suspected: a coagulation factor defect, or the presence of a lupus anticoagulant or of anti-factor antibodies.
  • A prostatic adenocarcinoma was suspected: a 5 cm prostatic tumour was found and the PSA level was 113 ng/mL.
  • The patient's disease was identified as a spontaneously acquired haemophilia A associated with prostatic adenocarcinoma.
  • [MeSH-major] Adenoma / complications. Hemophilia A / etiology. Prostatic Neoplasms / blood. Prostatic Neoplasms / complications
  • [MeSH-minor] Aged, 80 and over. Anemia / etiology. Diagnosis, Differential. Factor VIII / analysis. Hematoma. Humans. Male. Prostate-Specific Antigen / blood. Triazines

  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16829479.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Triazines; 55824-91-4 / 4-azido-7-phenylpyrazolo-(1,5a)-1,3,5-triazine; 9001-27-8 / Factor VIII; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


3. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H, Ogawa H: Is complete resection of hypertrophic adenoma of the prostate possible with TURP? J Nippon Med Sch; 2005 Jun;72(3):146-8
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is complete resection of hypertrophic adenoma of the prostate possible with TURP?
  • A lot of adenoma remains after transurethral resection of the prostate (TURP), the other hand transurethral enucleation of the prostate (TUE) is useful for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods
  • [MeSH-minor] Biomarkers / blood. Humans. Male. Prostate / pathology. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16046830.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 15
  •  go-up   go-down


Advertisement
4. Furuya S, Furuya R, Ogura H, Shimamura S, Araki T: [Transurethral resection for prostatic adenoma larger than 100 ml--preoperative treatment with interstitial laser coagulation of the prostate plus chlormadinone acetate as a treatment maneuver for safer operations]. Hinyokika Kiyo; 2005 Mar;51(3):159-64
Hazardous Substances Data Bank. CHLORMADINONE ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral resection for prostatic adenoma larger than 100 ml--preoperative treatment with interstitial laser coagulation of the prostate plus chlormadinone acetate as a treatment maneuver for safer operations].
  • Between August 1985 and March 2004, we performed transurethral resection of the prostate (TURP) in 18 patients with benign prostatic hyperplasia (BPH) whose prostatic volume was larger than 100 ml.
  • Group A consisted of a total of 14 cases: 10 cases whose mean prostate volume was 114 ml (100 to 137 ml) and 4 cases whose prostate volume was not measured before TURP but whose mean resected prostatic tissue weight was 113 g (105 to 118 g).
  • Group B consisted of 4 cases whose mean prostate volume was 110 ml (101 to 133 ml).
  • Patients in group B underwent interstitial laser coagulation of the prostate (ILCP) followed by oral chlormadinone acetate (CMA) therapy (50 mg/day); TURP was performed 6 months later, once the prostate volume had shrunk to an average of 76 ml (66 to 91 ml).
  • [MeSH-major] Chlormadinone Acetate / administration & dosage. Laser Coagulation. Preoperative Care. Prostate / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852668.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0SY050L61N / Chlormadinone Acetate
  • [Number-of-references] 24
  •  go-up   go-down


5. Goodman M, Bostick RM, Gross M, Thyagarajan B, Dash C, Flanders WD: Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update. Ann Epidemiol; 2010 Dec;20(12):955-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined measure of pro- and anti-oxidant exposures in relation to prostate cancer and colorectal adenoma risk: an update.
  • PURPOSE: We previously proposed an oxidative balance score (OBS) and illustrated its practical application by using data from previously completed case-control studies of two neoplasms - sporadic colorectal adenoma and prostate cancer.
  • When the OBS was divided into three approximately equal intervals, a comparison of the lowest to highest category showed similar adjusted ORs (95% CIs) of 0.34 (0.13-0.88) and 0.34 (0.14-0.86) for colorectal adenoma and prostate cancer, respectively.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] Mol Carcinog. 2000 Jan;27(1):18-23 [10642433.001]
  • [Cites] Cancer Lett. 2009 Sep 18;282(2):125-36 [19185987.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):773-96 [11375749.001]
  • [Cites] J Nutr. 2002 Apr;132(4):756-61 [11925473.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1279-84 [12433703.001]
  • [Cites] J Nutr. 2003 Mar;133 Suppl 3:875S-880S [12612173.001]
  • [Cites] Am J Epidemiol. 2004 May 15;159(10):983-92 [15128611.001]
  • [Cites] Cancer Causes Control. 2004 Jun;15(5):493-501 [15286469.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):9-16 [9511847.001]
  • [Cites] Dig Dis. 1998 May-Jun;16(3):152-8 [9618134.001]
  • [Cites] Cancer Metastasis Rev. 1998-1999;17(4):325-30 [10453275.001]
  • [Cites] Ann Epidemiol. 2007 May;17(5):394-9 [17462547.001]
  • [Cites] Ann Epidemiol. 2007 Nov;17(11):930; author reply 931 [17855113.001]
  • [Cites] Cancer Causes Control. 2008 Dec;19(10):1051-64 [18543072.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1271-9 [11142411.001]
  • (PMID = 21074110.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116795-03; United States / NCI NIH HHS / CA / R01 CA116795; United States / NCI NIH HHS / CA / R01 CA116795-01; United States / NCI NIH HHS / CA / R01 CA116795-03
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS242540; NLM/ PMC3008422
  •  go-up   go-down


6. Kravchick S, Cytron S, Stepnov E, Ben-Dor D, Kravchenko Y, Peled R: 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (>4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides. J Endourol; 2009 Jun;23(6):1007-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7 to 10 years' follow-up of 573 patients with elevated prostate-specific antigen (>4 ng/mL) or/and suspected rectal examination: biopsies protocol and follow-up guides.
  • PATIENTS AND METHODS: We included in this study 600 consecutive patients with suspicious findings on a per-rectum examination and/or an elevated prostate-specific antigen (PSA) (>4 ng/mL) level.
  • In all patients, we took from 8 to 16 biopsy samples, according to the prostate volume, from the lateral aspects.
  • TRUS-biopsy detected prostate cancer (PCa) in 257 patients (44.85% overall detection rate).
  • Prostate volumes were significantly smaller (52.9 +/- 22.4 cc vs 58.9 +/- 23.8 cc, P < 0.002) and the PSA/adenoma/prostate volumes ratio (ad-pro) ratio was higher (18.3 +/- 9 vs 13.96, P < 0/001) in the patients with PCa.
  • Patients with PCa underwent fewer biopsy procedures and biopsy sessions than patients without a diagnosis of PCa (14.9 +/- 8.9 vs 20.4 +/- 12, P < 0.001;1.3 +/- 0.6 vs 1.7 +/- 0.9, P < 0.001).
  • Numbers of biopsy procedures and PSA/ad-pro ratio were the strongest predictive factors for PCa detection (P < 0.001).
  • CONCLUSIONS: In patients with a prostate volume >or=53 cc and PSA/ad-pro ratio >or=18, the optimal biopsy cores should be >or=15.

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19456240.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Verger-Kuhnke AB, Reuter M, Epple W, Ungemach G, Beccaría ML: [Combined treatment of prostatic adenoma with the 80 Watt KTP-laser and low-pressure transurethral resection]. Actas Urol Esp; 2006 Apr;30(4):394-401
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined treatment of prostatic adenoma with the 80 Watt KTP-laser and low-pressure transurethral resection].
  • [Transliterated title] Tratamiento combinado del adenoma prostático con el KPT-láser de 80 Watt y la resección transuretral de baja presión.
  • INTRODUCTION: The purpose of this prospective study is to determine the effectiveness of method for vaporisation and elimination of the prostate adenoma.
  • The additional Resection was carried out in those patients with large adenomas or to have accentuated middle lobule.
  • CONCLUSION: Our study reveals the advantages of combining both operative procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Adenoma / surgery. Laser Therapy / methods. Prostatectomy / methods. Prostatic Neoplasms / surgery. Video-Assisted Surgery / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16838611.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Martov AG, Merinov DS, Kornienko SI, Gushchin BL, Ergakov DV, Mustafaev EM, Borisenko EA: [Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma]. Urologiia; 2006 Mar-Apr;(2):25-32
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative urological complications of transurethral electrosurgical interventions on the prostate for adenoma].
  • The aim of the study was comparison of urological complications after transurethral resection and its low-invasive alternatives: vaporization, rotoresection, vaporization resection, prostatic incision.
  • Case histories were studied of 5401 patients operated endoscopically for prostatic adenoma in 1991-2003.
  • No hemorrhagic complications occurred in rotoresection, no hemotransfusions were made in vaporization and vaporizing resection, prostatic incision was complicated by hemorrhage only in 0.9% cases.
  • [MeSH-major] Electrosurgery. Postoperative Complications / diagnosis. Postoperative Hemorrhage / diagnosis. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate
  • [MeSH-minor] Humans. Infection / diagnosis. Infection / therapy. Male. Prostatectomy / methods. Treatment Outcome. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / therapy

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708585.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


9. Bogdanov AB, Luk'ianov IV, Veliev EI: [Using doxasosine and finasteride combination in the treatment of prostate adenoma]. Urologiia; 2006 Sep-Oct;(5):59-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using doxasosine and finasteride combination in the treatment of prostate adenoma].
  • The study was made in 2005-2006 of efficacy and safety of combined use of doxasosine and finasteride in patients (n = 50, age 53-83) with symptoms of lower urinary tract dysfunction (LUTD) caused by prostatic adenoma.
  • LUTD severity by IPSS, size of the prostate, maximal and mean urinary flow velocity, functional capacity of the urinary bladder, residual urine, blood pressure, a PSA level, sexual function, were assessed at baseline and after the treatment.
  • The size of the prostate diminished from 55.8 to 46 cm(3) (p < 0.01).
  • Thus, the proposed scheme of combined treatment improves quality of life, voiding; lowers residual urine; is well tolerated; can be recommended as a basic scheme of treatment in patients with a risk of prostatic adenoma progression.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Doxazosin / therapeutic use. Enzyme Inhibitors / therapeutic use. Finasteride / therapeutic use. Prostatic Hyperplasia / drug therapy. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444154.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


10. Zhang Y, Du CJ, Xu G, Chen JM, Jing X: [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g]. Zhonghua Nan Ke Xue; 2007 Dec;13(12):1091-3
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral holmium laser enucleation for prostate adenoma greater than 100 g].
  • OBJECTIVE: To evaluate the effect of transurethral holmium laser enucleation of the prostate (HoLEP) for prostate adenoma greater than 100 g.
  • METHODS: Sixty BPH patients with the prostate larger than 100 g were randomized to two treatment groups of HoLEP (n = 32) and open prostatectomy (n = 28).
  • Comparisons were made between the two groups in operating time, blood loss, bladder irrigating time, catheterization time and hospital stay, as well as in the international prostate symptom score (IPSS), quality of life (QOL) score, maximum urinary flow rate (Qmax) and postvoid residual volume (PVR) before and 3 months after the surgery.
  • CONCLUSION: HoLEP and open prostatectomy are equally effective procedures for removal of large prostate adenomas, but the former is a better surgical option for prostate adenomas larger than 100 g for its greater safety, less pain and faster recovery.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18284057.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] W1XX32SQN1 / Holmium
  •  go-up   go-down


11. Tkachuk VN, Tkachuk IN: [Vitaprost forte efficacy in patients with prostatic adenoma]. Urologiia; 2008 Jul-Aug;(4):34-7
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte efficacy in patients with prostatic adenoma].
  • Efficacy and safety of a new bioregulatory peptide vitaprost forte was studied in 30 patients with prostatic adenoma.
  • It is shown that this drug relieves clinical symptoms of the disease, improves quality of life, uroflowmetric parameters, reduces the size of the prostatic gland.
  • Vitaprost forte is more effective in patients with prostatic adenoma combined with chronic prostatitis.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Aged. Chronic Disease. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate / pathology. Prostate / physiopathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19058362.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


12. Sergienko NF, Vasil'chenko MI, Begaev AI, Shekochikhin AV, Shershnev SP, Reĭniuk OL, Lototskiĭ MM: [Transvesical extraurethral adenomectomy and transurethral prostatic resection in adenoma: specific features]. Urologiia; 2010 Sep-Oct;(5):29-35
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transvesical extraurethral adenomectomy and transurethral prostatic resection in adenoma: specific features].
  • The procedure of transvesical extraurethral adenomectomy (EUA) and the results of its application were characterized in comparison with transurethral resection (TUR) of the prostate in adenoma.
  • Dissection is conducted of the affected posterior half-round of only proximal prostatic part of the urethra in unaffected anterior and lateral urethral surface.
  • TUR of the prostate is made without incision of the soft tissues of the anterior abdominal wall, but with removal of the prostatic portion of the urethra, sphincter mechanism of the bladder.
  • After TUR the prostate contains residual adenomatous tissue, inner wound cavity in adenoma bed.
  • The wound of the anterior abdominal wall, anterior wall of the bladder and vesicourethral segment healed by primary intention for 10-14 days, while adenoma bed heals for 6-18 months.
  • EUA does not cause such complication as "adenoma bed", urethral stricture, scar deformation of the bladder neck, urinary incontinence.
  • Radical EUA produces complications 5 times less frequently than TUR of the prostate.
  • [MeSH-major] Prostate / surgery. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21260939.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


13. Miller AM, Iaroshenko VP, Soroka PV, Stakhnev EIu: [Efficacy of vitaprost forte in patients with prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):50, 52-4
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in patients with prostatic adenoma].
  • The trial of a new bioregulatory peptide vitaprost forte (100 mg rectal suppositoria) in 30 patients with prostatic adenoma demonstrated that this drug attenuates clinical symptoms of the disease, improves quality of life, uroflowmetric parameters and reduces size of the prostate.
  • Vitaprost forte is more effective in patients with prostatic adenoma in combination with chronic prostatitis, has antiaggregant and anticoagulant properties, stimulates synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostate resulting in regressioin of edema, activity of inflammation in prostatic diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069497.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


14. Kamalov AA, Efremov EA, Dorofeev SD, Mel'nik IaI, Okhobotov DA: [Vitaprost forte in the therapy of patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):39-44, 47
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vitaprost forte in the therapy of patients with prostatic adenoma].
  • Active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland.
  • Prostatic extract has an organotropic effect in respect to the prostatic gland.
  • It inhibits proliferative activity of cells and, therefore, development of prostatic adenoma, reduces edema and inflammation activity in prostatic diseases.
  • Our study has shown that rectal suppositories vitaprost forte, as monotherapy of prostatic adenoma, produces a statistically significant moderate decrease of prostate size.
  • Rectal suppositories vitaprost forte can be used as monotherapy of prostatic adenoma in patients with moderate infravesical obstruction irrespective of age and concurrent diseases.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Animals. Cattle. Drug Administration Schedule. Humans. Male. Organ Size. Prostate / chemistry. Prostate / pathology. Sulfonamides / administration & dosage. Sulfonamides / therapeutic use. Suppositories. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722619.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Sulfonamides; 0 / Suppositories; 0 / Vitaprost; G3P28OML5I / tamsulosin
  •  go-up   go-down


15. Sitdykova ME, Zubkov AIu: [Efficacy of vitaprost forte in the treatment of prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):27-30
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of vitaprost forte in the treatment of prostatic adenoma].
  • Thirty patients with a documented diagnosis of prostatic adenoma were treated with vitaprost forte (100 mg rectal suppositoria) for 60 days.
  • Its efficacy was proved by improved urodynamics of the lower urinary tract, reduction of prostatic size.
  • Vitaprost forte is recommended for treatment of patients suffering from prostatic adenoma with mild and moderate symptoms.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169719.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Vitaprost
  •  go-up   go-down


16. Traore CB, Kamate B, Toure ML, Diarra T, Bayo S: [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases]. Mali Med; 2006;21(4):32-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anatomopathologic, clinical and radiologic aspects of benign tumors of the prostate in Mali, 759 cases].
  • [Transliterated title] Aspects anatomopathologiques, cliniques et radiologiques des tumeurs benignes de la prostate au Mali, a propos de 759 cas.
  • The benign prostate tumours are dominated by prostatic adenomyoma.
  • The objective of this work is to describe the anatomo-pathological, clinical and radiological aspects of benign prostate tumours in Mali.
  • It has involved 759 patients who had histological confirmed prostate adenoma in the Department of Urology in Point G University Hospital.
  • The patients were classified according to age, the clinical exam, the rate of prostate specific antigen (PSA), the sonogram, the macro and microscopic exam.
  • The apical part of the prostate is the area mostly involved.
  • "The night pollakiuria" was the primarily clinical sign in all patients; the prostate specific antigen (PSA) is high among more than 80%.
  • [MeSH-major] Adenomyoma / pathology. Adenomyoma / radiography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / radiography. Urology Department, Hospital / statistics & numerical data
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Hospitals, University. Humans. Incidence. Male. Mali / epidemiology. Middle Aged. Prostate-Specific Antigen / blood. Retrospective Studies. Urination Disorders / etiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437843.001).
  • [ISSN] 0464-7874
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mali
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


17. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN: [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection]. Urologiia; 2008 Jan-Feb;(1):27, 29, 31
Hazardous Substances Data Bank. FINASTERIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Finasteride preoperative preparation of patients with prostatic adenoma to transurethral prostatic resection].
  • Finasteride effect before transurethral resection (TUR) of the prostatic gland was studied in 88 patients with prostatic adenoma (PA).
  • Finasteride reduced blood flow in prostatic tissue, density of the vascular plexus, epithelium/stroma coefficient from 1.26 to 0.84.
  • [MeSH-major] Blood Loss, Surgical / prevention & control. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Preoperative Care. Prostate / surgery. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18652018.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride
  •  go-up   go-down


18. Aliaev IuG, Grigorian VA, Tsarichenko DG, Lokshin KL, Kharchilava RR: [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control]. Urologiia; 2006 May-Jun;(3):8-12
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electroresection of prostatic adenoma under transrectal ultrasonic control].
  • The aim of the study was to improve the results of transurethral prostatic resection (TUPR) by introduction of intraoperative transrectal ultrasonic investigation (TRUSI) and to determine topographic-anatomic features of the prostate, intraorgan relations of adenomatous nodes and surgical prostatic capsule on-line in TUPR.
  • A total of 64 patients with prostatic adenoma (PA) of the second degree aged 52-79 participated in the study.
  • The patients were divided into two study groups (15 patients with volume of the prostate 36.5-78.6 cm3 and 17 patients with prostate size 80-4-141.2 cm3) in which TRUSI was performed and two control groups (n = 14, size 34.9 to 79.2 cm3 and n = 18, size 81.7-130.8 cm3, respectively) who have not undergone intraoperative TRUSI.
  • Control TRUSI on day 7 after TUPR registered mean volume of the prostate to be 19.3 +/- 1.4 cm3 in group 1, 39.8 +/- 2.1 cm3 in group 2, 28.1 +/- 1.6 cm3 in group 3, 47.7 +/- 3.2 cm3 in group 4.
  • Thus, intraoperative TRUSI provides information which helps the surgeon to orient in the course of surgery and minimize the threat of perforation of the prostatic capsule; minimizes intraoperative complications and enhances efficacy of radical transurethral electroresection of prostatic hyperplasia improving long-term outcomes of the operation.
  • [MeSH-major] Intraoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatic Hyperplasia / ultrasonography. Transurethral Resection of Prostate. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889081.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


19. Ergakov DV, Martov AG, Maksimov VA: [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit]. Urologiia; 2009 Jan-Feb;(1):24-8
MedlinePlus Health Information. consumer health - Herbal Medicine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Improvement of surgical outcomes in patients with prostatic adenoma due to postoperative administration of the drug likoprofit].
  • We studied efficacy and safety of likoprofit pharmacotherapy in patients early after transurethral resection (TUR) of the prostate.
  • Likoprofit showed high efficacy early after TUR for prostatic adenoma in correction of irritative disorders of urination (frequent voiding, urges, painful urination with small urine portions).
  • [MeSH-major] Phytotherapy. Plant Preparations / administration & dosage. Postoperative Care. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432230.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Preparations
  •  go-up   go-down


20. Bratchikov OI, Ambarian AA, Shumakova EA, Khmaruk AP, Kriukov AA, Trifonov EIu, Mikhaĭlov DV, Abduldzhalil Shukri MA: [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma]. Urologiia; 2010 Jan-Feb;(1):38-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Etiological and prognostic aspects of renal failure in patients with prostatic adenoma].
  • The aim of our study was to assess the causes of renal failure in patients with prostatic adenoma (PA) and outcomes after draining of the urinary bladder.
  • We found that age, prostate volume, PA growth pattern, urinary tract infection, concomitant pathology (arterial hypertension, diabetes mellitus, atherosclerosis) do not correlate with a serum creatinine level.
  • [MeSH-major] Creatinine / blood. Prostatic Hyperplasia / complications. Renal Insufficiency / etiology

  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20886730.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


21. Teodorovich OV, Shatokhin MN, Mal'tsov VN, Konoplia AI, Loktiononv AL, Krasnov AV: [Correction of local immunometabolic disturbances combined with chronic prostatitis in prostatic adenoma]. Urologiia; 2010 Sep-Oct;(5):22-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correction of local immunometabolic disturbances combined with chronic prostatitis in prostatic adenoma].
  • We compared local immunometabolic effects of two dosage forms of longidase in patients with prostatic adenoma (PA) in combination with chronic prostatitis (CP) in the postoperative period.
  • Transurethral resection (TUR) of the prostate was conducted in 81 patients aged 50-70 years suffering from PA and CP.
  • [MeSH-major] Prostatic Hyperplasia / blood. Prostatic Hyperplasia / immunology. Prostatitis / blood. Prostatitis / immunology


22. Martov AG, Merinov DS, Borisenko EA: [Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma]. Urologiia; 2006 May-Jun;(3):12-3, 15-6
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral plasmokinetic resection and vaporization is a new method of treatment of prostatic adenoma].
  • Clinical efficacy and safety ofplasmakinetic resection and vaporization were studied in 28 patients with prostatic adenoma (mean age 68 years, mean size of the prostate 65 cm3).
  • Complaints by IPSS scale, quality of life index, results of uroflowmetry and prostatic ultrasonography were assessed before surgery (transurethral plasmakinetic resection and prostatic vaporization) and 1, 3, 6 and 12 months after it.
  • Pilot results point to high clinical efficacy and safety of plasmakinetic resection and vaporization in patients with prostatic adenoma.
  • [MeSH-major] Laser Therapy / methods. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889082.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


23. Mustafaev EM, Martov AG, Naumov AG, Siniukhin VN, Shakir F, Merinov DS, Amelin AV, Al'bitskaia AIu: [The role of ozone therapy in prevention of pyoinflammatory complications after transurethral resection of prostatic adenoma]. Urologiia; 2007 Jan-Feb;(1):18-23, 27
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of ozone therapy in prevention of pyoinflammatory complications after transurethral resection of prostatic adenoma].
  • The study of efficacy of ozone therapy (OT) in preparation of patients with prostatic adenoma (PA) and cystostoma for transurethral resection (TUR) of PA included 20 PA patients with cystostomic drainage who had undergone PA TUR and preoperative preparation with OT sessions.
  • OT efficacy was assessed by the rate of pyoinflammatory complications (PIC), results of immunological examination, positive changes in prostatic secretion, urine analysis, total blood count, degree ofbacteriuria.
  • Mean control count of leukocytes in prostatic secretion fell in both groups.
  • [MeSH-major] Ozone / therapeutic use. Physical Therapy Modalities. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Prostatitis / prevention & control. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Ozone.
  • Hazardous Substances Data Bank. OZONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471993.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 66H7ZZK23N / Ozone
  •  go-up   go-down


24. Trapeznikova MF, Dutov VV, Dolgovq AG, Urenkov SB: [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis]. Urologiia; 2008 Sep-Oct;(5):39-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis].
  • We studied efficacy and safety of prostamol-Uno (PU) monotherapy in patients with prostatic adenoma (PA) comorbid with chronic abacterial prostatitis (CAP) in a clinical open trial including 45-year-old males aged over 45 years with PA comorbid with CAP, having irritative and obstructive symptoms by IPSS above 8 points and duration 6 months or longer, by NIH-CPSI above 10 points and duration 3 months or longer.
  • The patients had Qmax from 5 to 15 ml/s, urine volume 100-350 ml, residual urine volume under 150 ml, prostate size more than 25 cm3, PSA level under 4 ng/ml and no bacterial growth in the third urine portion seeding and/or prostatic secretion.
  • The effect was assessed by the disease history, complaints, digital rectal examination of the prostate, the disease symptoms by IPSS, quality of life (QoL), NIH-CPSI, bacteriological tests of the urine and prostatic secretion, urinalysis, Nechiporenko test in 3 urine portions.
  • Uroflowmetry, ultrasonic investigation of the urinary bladder and prostate, transrectal energy dopplerography of the prostate, PSA assay in the blood serum were made in all the patients.
  • Spectral doppler examination detected improvement in prostatic blood flow after PU treatment in 16 (53.3%) patients.
  • Thus, PU effectively reduces irritative and obstructive symptoms typical for prostatic adenoma in combination with CAP.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy
  • [MeSH-minor] Blood Pressure / drug effects. Chronic Disease. Electrocardiography. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Quality of Life. Urination / drug effects

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069494.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


25. Shalekenov BU, Kuandykov EA, Anafin TG, Shalekenov SB: [Photoselective laser vaporization of complicated prostatic adenoma]. Urologiia; 2007 Nov-Dec;(6):73-5
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective laser vaporization of complicated prostatic adenoma].
  • The aim of the study was to determine indications for use of photoselective laser vaporization of the prostate (PVP) in clinical practice and to evaluate long-term results of this method.
  • Since September 2005 to February 2007 a total of 106 patients aged 55-95 years with prostatic adenoma were operated.
  • Photoselective laser vaporization improves quality of life in prostatic adenoma at all stages of the disease.
  • [MeSH-major] Laser Therapy. Prostatic Hyperplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649665.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


26. Zhao Y, Chen J, Wang M, Sun P, Li L, Zhang H, Jin X: Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients. Saudi Med J; 2010 Dec;31(12):1320-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoselective vaporization combined with bipolar transurethral resection for the treatment of large prostate adenoma in high-risk patients.
  • OBJECTIVE: To evaluate the safety and effectiveness of the combined photoselective vaporization of the prostate (PVP) and bipolar transurethral resection of the prostate (TURP) in high-risk symptomatic patients with large prostates.
  • One hundred and one patients presenting with various kinds of systematic diseases, and with an American Society of Anesthesiologists score of 3 or greater underwent PVP plus bipolar TURP for severe lower urinary tract symptoms due to benign prostatic hyperplasia with prostatic volume greater than 80 ml.
  • The International Prostate Symptom Score (IPSS) and quality-of-life questionnaire (IPPS-QoL), maximum flow rates (Qmax), postvoid urine residues (PVR), and MRI prostatic volumes were recorded.
  • The mean pre- and post- operative prostate volumes were 102.2 ± 33.1 ml and 40.4 ± 15.6 ml.
  • [MeSH-major] Adenoma / therapy. Prostatic Neoplasms / therapy. Transurethral Resection of Prostate. Volatilization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21135994.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


27. Tkachuk VN, Al'-Shukri SKh, Tkachuk IN, Mosoian MS: [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. Urologiia; 2009 Nov-Dec;(6):25-7
Hazardous Substances Data Bank. FINASTERIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers].
  • Pharmacotherapy of prostatic adenoma is based in present-day practice primarily on two basic groups of medicines--inhibitors of 5alpha-reductase and blockers of alphal-adrenoreceptors.
  • Our trial included 98 patients with prostatic adenoma aged 59-79 years given combined treatment with finasteride (inhibitor of 5alpha-reductase) made in Hungary (prosteride, Gedeon Richter) and an uroselective blocker of alpha1-adrenoreceptors sonisin (Gedeon Richter, Hungary).
  • After 12-month combined treatment symptoms of the disease reduced by IPSS from 17.9 +/- 1.8 to 3.9 +/- 0.9 points, Qmax rose from 8.8 +/- 0.3 to 14.6 +/- 0.3, residual urine volume diminished from 91.7 +/- 8.5 to 31.7 +/- 4.4, the size of the prostate reduced from 72.4 +/- 2.9 to 50.6 +/- 3.7, quality of life improved 2-fold.
  • Combined administration of finasteride (prosteride) and alpha1-adrenoblocker tamsulosine (sonisine) meet three principles of pharmacotherapy of prostatic adenoma: prevents progression of the disease and surgical treatment, relieves symptoms and improves quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors. Adrenergic alpha-Antagonists / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169718.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


28. Mazo EB, Krivoborodov GG, Sukhanov SV, Ivanov RV, Sereda EG: [Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma]. Urologiia; 2007 Nov-Dec;(6):55, 57-60
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma].
  • An active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland.
  • The prostatic extract has an organ-tropic action in relation to the prostate: inhibits proliferative activity of the cells leading to suppression of prostatic adenoma development, reduces edema and activity of inflammation in prostatic diseases.
  • The new vitaprost tablets can decrease volume of the prostate (this trend was not significant), relieve infravesical obstruction and irritation, improve quality of life.
  • Vitaprost tablets coated with intestinally soluble cover are recommended as a component of combined treatment of prostatic adenoma in patients with moderate infravesical obstruction irrespective of the patients' age and concomitant diseases.
  • [MeSH-major] Peptides / administration & dosage. Prostatic Hyperplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649662.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Peptides; 0 / Tablets, Enteric-Coated; 0 / Vitaprost
  •  go-up   go-down


29. Razumov SV, Egorov AA: [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma]. Urologiia; 2007 May-Jun;(3):47-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma].
  • A total of 58 patients with prostatic adenoma (PA) treated with prostamol Uno in combination with tamsulosin were divided into two groups: 28 patients continued the above combined therapy, 30 patients were switched to monotherapy with prostamol Uno.
  • All the patients were examined in the course of 4 visits according to standard protocol requesting information on the disease history, complaints, digital rectal examination, IPSS questionnaire, QOL, uroflowmetry with test for residual urine, transrectal ultrasonography of the prostate, blood test for PSA.
  • To the end of treatment month 9 the size of the prostate diminished by 6.7 cm3, on the average, in both groups.
  • [MeSH-major] Adrenergic alpha-1 Receptor Antagonists. Adrenergic alpha-Antagonists. Plant Extracts. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Drug Therapy, Combination. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724829.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Adrenergic alpha-Antagonists; 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


30. Verger-Kuhnke AB, Reuter MA, Epple W, Ungemach G, Beccaría ML: [Photoselective vaporization with the 80-watt KTP-laser (kalium-titanyl-phosphate) and low-hydraulic-pressure TURP in the treatment of BPH: our experience with 230 cases]. Arch Esp Urol; 2007 Mar;60(2):167-77
Hazardous Substances Data Bank. TITANIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La vaporizacion fotoselectiva de la HPB con el KTP-laser (kalium- titanyl-phosphat) de 80 watt y la RTU-P de baja presion hidraulica, experiencia en 230 casos.
  • The additional Resection was carried out in those patients with great adenomas or having a big middle lobe.
  • The group 1 (n: 50) just by laser treatment and small adenomas, the haemoglobin was reduced a 3.2% and nobody required a transfusion.
  • Group 2 (n: 180) with combined treatment of KTP-laser and TUR-P in great adenomas, the haemoglobin was reduced in average 13.7% after the intervention; 2 patients (1.1%) needed a transfusion.
  • CONCLUSION: Our study shows the advantages of combining both, the advantages to combine both surgical procedures to mainly obtain a better result in the ablation of the prostate adenoma in prostates of great size.
  • [MeSH-major] Laser Therapy / instrumentation. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484484.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Phosphates; 12690-20-9 / potassium titanylphosphate; D1JT611TNE / Titanium
  •  go-up   go-down


31. Neĭmark AI, Snegirev IV, Neĭmark BA: [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma]. Urologiia; 2006 Mar-Apr;(2):75, 77-9
MedlinePlus Health Information. consumer health - Urinary Tract Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transrectal magnetotherapy of the prostate from Intramag device in prophylaxis of postoperative complications of transurethral resection of prostatic adenoma].
  • The authors analyse preoperative preparation of 91 patients with benign prostatic hyperplasia (BPH).
  • Two groups of patients received conventional preparation (group 1) and magnetotherapy (group 2) before TUR of the prostate.
  • The examination covered immune system, bacteriological indices of urine and prostatic tissue.
  • Conventional preoperative preparation fails to correct immunity, to change bacterial urine flora, to improve hemodynamics in the prostate.
  • [MeSH-major] Ferrosoferric Oxide / therapeutic use. Physical Therapy Modalities / instrumentation. Postoperative Complications / prevention & control. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Tract Infections / prevention & control
  • [MeSH-minor] B-Lymphocytes / immunology. Humans. Leukocyte Count. Male. Perioperative Care / methods. Prostate / microbiology. Rectum. T-Lymphocytes / immunology. Urine / microbiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708596.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] XM0M87F357 / Ferrosoferric Oxide
  •  go-up   go-down


32. Vinarov AZ, Aliaev IuG, Apolikhin OI, Mazo EB, Darenkov SP, Demidko IuL, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression]. Urologiia; 2010 Nov-Dec;(6):3-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression].
  • PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls.
  • Administration of PU significantly increased urinary flow rate though in the controls urinary flow rate decreased, size of the prostate diminished and increased, respectively.
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged. Organ Size. Prostate / drug effects. Prostate / ultrasonography. Prostate-Specific Antigen / blood. Quality of Life. Risk. Treatment Outcome. Urinary Bladder / physiopathology. Urinary Bladder / ultrasonography. Urinary Retention / etiology. Urinary Retention / physiopathology. Urinary Retention / prevention & control. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21433319.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


33. Likhin FA, Bartnovskiĭ AE, Vdovichenko KK, Abramov AA, Belokhvostov AS: [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma]. Urologiia; 2005 Jul-Aug;(4):12-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of methyl-specific PCR-test of glutathione-S-transferase P1 gene in plasm DNA and cellular urinary precipitate for differential diagnosis of prostatic adenoma and adenocarcinoma].
  • The study was made of possibilities of methyl-specific PCR-test of glutathione-S-transferase P1 (GSTP1) gene in differential diagnosis of prostatic cancer: sensitivity of the test, comparison of reagents of Russian and foreign production.
  • Blood plasm and cellur urinary precipitate DNA was investigated in patients with prostatic adenocarcinoma.
  • The results show that the above test with domestic reagents is rather perspective for differential diagnosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. DNA, Neoplasm / analysis. Polymerase Chain Reaction / methods. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] DNA / blood. DNA / metabolism. DNA / urine. DNA Methylation. Diagnosis, Differential. Humans. Male. Prostatic Hyperplasia / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158738.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


34. Malek RS: [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma]. Urologiia; 2006 Sep-Oct;(5):11-5
Hazardous Substances Data Bank. MONOPOTASSIUM DIHYDROGEN PHOSPHATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photoselective vaporization with high-performance potassium-titanil-phosphate laser in the treatment of obstructive prostatic adenoma].
  • Novel laser technologies were used in development of a new highly effective and simple method of laser adenomectomy (LA) called photoselective vaporization of the prostate (PVP).
  • Efficacy of PVP is comparable to transurethral resection (TUR) of prostatic adenoma but is more cost-effective than TUR or other low-invasive techniques.
  • Therefore, PVP is very promising in surgical treatment of obstructive prostatic adenoma and may become a leading surgical method in this disease.
  • [MeSH-major] Laser Therapy. Prostatectomy / methods. Prostatic Hyperplasia / surgery
  • [MeSH-minor] Animals. Humans. Male. Phosphates. Potassium Compounds. Transurethral Resection of Prostate / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DIPOTASSIUM PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17444145.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Phosphates; 0 / Potassium Compounds; 16068-46-5 / potassium phosphate
  •  go-up   go-down


35. Xiao GQ, Burstein DE, Miller LK, Unger PD: Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Jun;130(6):805-10
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: immunohistochemical evaluation for its etiology and differentiation from prostatic adenocarcinoma.
  • CONTEXT: Nephrogenic adenoma is a rare benign lesion of the urinary tract.
  • Owing to its strong association with a history of urinary tract irritation, nephrogenic adenoma was initially thought to originate from urothelial metaplasia; however, no solid proof of this association has been found.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic carcinoma, particularly when dealing with lesions from the prostatic urethra.
  • OBJECTIVE: To elucidate a possible histogenic relationship between nephrogenic adenoma and renal tubules, and also to evaluate the role of immunohistochemistry in the diagnostic distinction between nephrogenic adenoma and prostate carcinoma.
  • DESIGN: Immunohistochemical studies were performed for P504S, prostate-specific antigen, CD10, p63, and epithelial membrane antigen on 9 cases of nephrogenic adenoma, 10 cases of normal renal parenchyma, and 10 cases of prostatic tissue, both benign and malignant.
  • RESULTS: Nephrogenic adenoma shares the same immunohistochemical profile as distal renal tubules: both are positive for P504S and epithelial membrane antigen and negative for p63, CD10, and prostate-specific antigen.
  • Prostatic adenocarcinoma tissue was positive for P504S and prostate-specific antigen, and normal prostatic gland tissue was positive for prostate-specific antigen and negative for P504S; p63-stained basal cells in normal prostatic gland tissue but did not react with prostatic adenocarcinoma tissue.
  • The CD10 inconsistently stained normal and neoplastic prostatic gland tissue.
  • Epithelial membrane antigen stain was negative in prostatic carcinoma, with rare occasional reactivity in normal prostatic glands.
  • CONCLUSION: These findings provide supporting evidence that nephrogenic adenoma is derived from distal renal tubules.
  • Our results also demonstrated that the combination of P504S and prostate-specific antigen with epithelial membrane antigen is a valuable tool in distinguishing prostatic carcinoma from nephrogenic adenoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Immunohistochemistry / methods. Prostatic Neoplasms / diagnosis. Urologic Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Mucin-1 / analysis. Racemases and Epimerases / analysis. Urothelium / chemistry. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740031.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


36. Borisov VB: [Treatment of prostatic adenoma]. Urologiia; 2010 Jul-Aug;(4):42-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of prostatic adenoma].
  • We used lymphotropic therapy in addition to standard treatment in 116 of 232 patients with benign prostatic hyperplasia.
  • Improvement in general condition of the patients, symptoms of infravesical obstruction, size of the prostate, urinary flow rate demonstrated high efficacy of lymphotropic therapy leading to a higher rate of persistent remission and higher quality of life.
  • [MeSH-major] 5-alpha Reductase Inhibitors / therapeutic use. Adrenergic alpha-1 Receptor Antagonists / therapeutic use. Anti-Bacterial Agents / therapeutic use. Finasteride / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20967982.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Adjuvants, Immunologic; 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Sulfonamides; 57GNO57U7G / Finasteride; EC 3.2.1.- / lidase; EC 3.2.1.35 / Hyaluronoglucosaminidase; G3P28OML5I / tamsulosin
  •  go-up   go-down


37. Iagudaev DM, Sorokatyĭ AE, Martov AG, Geĭnits AV, Markova MV: [Photodynamic therapy of prostatic adenoma]. Urologiia; 2007 Jul-Aug;(4):34-7
Hazardous Substances Data Bank. GLUCOSAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Photodynamic therapy of prostatic adenoma].
  • We were the first to study feasibility of photodynamic therapy (PDT) for prostatic adenoma using photosensitizer from chlorine group--photoditasine.
  • [MeSH-major] Glucosamine / analogs & derivatives. Photochemotherapy. Photosensitizing Agents / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915446.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 3329-30-4 / N-methylglucosamine; N08U5BOQ1K / Glucosamine
  •  go-up   go-down


38. Błaut K, Wiśniewski P, Syrenicz A, Sworczak K: Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog. Neuro Endocrinol Lett; 2006 Oct;27(5):569-72
Hazardous Substances Data Bank. GOSERELIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog.
  • LHRH analogs have become a promising modality in prostate cancer therapy as an alternative to surgical castration, and the use of these agents is generally considered to be safe.
  • Since now, only few cases of an apoplexy of previously undiagnosed pituitary adenoma (usually gonadotropinoma) at the beginning of therapy have been described in the medical literature.
  • We present a case of a 74 year old patient who was diagnosed of prostate cancer at the age of 68.
  • During 6 years of follow-up there was no evidence of prostate cancer recurrence.
  • [MeSH-major] Adenoma / complications. Gonadotropin-Releasing Hormone / analogs & derivatives. Neoplasms, Multiple Primary / diagnosis. Pituitary Apoplexy / etiology. Pituitary Neoplasms / complications. Prostatic Neoplasms / drug therapy


39. Pushkar' DIu, Dul'kin LM, Pletner DL, Bormotin AV, Liaginskiĭ AB: [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma]. Urologiia; 2009 Nov-Dec;(6):22-4
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advanced microwave thermotherapy (PLFT) as a method of choice in the treatment of complicated, inoperable prostatic adenoma].
  • The aim of our study was assessment of efficacy of PLFT technique on ProstaLund CoreTHerm unit in nanagement of acute urine retention in patients with prostatic adenoma.
  • We treated 31 patients with prostatic adenoma (age 58-97, mean age 74 years, volume of the prostatic gland from 32 to 188 ml); 11 patients had suprapubic fistula, 8 carried urethral catheter for acute urinary retention.
  • PLFT destroyed 15 +/- 5% prostatic tissue in each of the treated patients.
  • Thus, PLFT is a highly effective and save treatment of prostatic adenoma and can be recommended as a standard management of patients with acute urinary retention at high surgical risk.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / therapy. Recovery of Function. Transurethral Resection of Prostate / methods. Urination

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169717.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


40. Gorilkovskiĭ LM, Zingerenko MB: [Efficacy and safety of tulosine in patients with prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):60, 62-5
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of tulosine in patients with prostatic adenoma].
  • The study of tulosine (tamsulosine) efficacy and safety was made in 92 patients with lower urinary tract symptoms (LUTS) due to prostatic adenoma (PA).
  • Ultrasound investigation found no significant changes in the adenoma size.
  • Thus, tulosine is a safe and effective drug for treatment of prostatic adenoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Sulfonamides / adverse effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526876.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


41. Pavlov VN, Kazikhinurov AA, Ishemgulov RR, Mustafin AT: [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method]. Urologiia; 2008 Jan-Feb;(1):31-2, 34-5
Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Changes in microcirculation of the urinary bladder in patients with stage II prostatic adenoma depending on the treatment method].
  • To determine microcirculation in the wall of the urinary bladder in prostatic adenoma, we used a laser analyzer of capillary circulation LAKK-01.
  • Two groups participated in the trial: 105 males with stage II prostatic adenoma (the study group) and 25 volunteers (the control group).
  • In stage II prostatic adenoma the above microcirculation decreased to a subcritical perfusion level.
  • Significantly earlier and complete recovery of microcirculation was observed in patients who had taken cardura (Pfizer) in a dose 2 mg/day for 3 months after transurethral resection of prostatic gland.
  • Thus, 2 mg/day cardura (Pfizer) in patients with prostatic adenoma of stage II after TUR of the prostate promotes early and effective recovery of microcirculation.
  • [MeSH-major] Prostatic Hyperplasia / physiopathology. Prostatic Hyperplasia / therapy. Recovery of Function. Urinary Bladder / blood supply

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649676.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; NW1291F1W8 / Doxazosin
  •  go-up   go-down


42. Martov AG, Ergakov DV: [The experience in dutasteride use before transurethral prostatic resection for large adenoma]. Urologiia; 2008 Jul-Aug;(4):46, 48-50, 52
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The experience in dutasteride use before transurethral prostatic resection for large adenoma].
  • Dutasterid is a novel effective inhibitor of 5-alpha reductase of both types which can be used in patients with large (more than 80 cm3) prostatic adenoma to prevent intra- and postoperative hemorrhagic complications before transurethral resection of the prostate (TUR).
  • The trial included 70 males aged 67-82 years (mean age 74 years) with large size prostatic adenoma (more than 80 cm3) having indications for prostatic TUR.
  • Patients with coagulopathy, suspected prostatic cancer, previous treatment with 5-alpha reductase inhibitors were not included.
  • We recommend to begin dutasterid administration in a dose 0.5 mg for 1 month before TUR not only for patients with larger prostate (greater than 80 cm3) but with smaller prostates (30-80 cm3) for prevention of hemorrhagic complications and better conditions for surgery.
  • [MeSH-major] Azasteroids / administration & dosage. Enzyme Inhibitors / administration & dosage. Preoperative Care. Prostatic Hyperplasia / surgery. Urogenital Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054996.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / 5-alpha Reductase Inhibitors; 0 / Azasteroids; 0 / Enzyme Inhibitors; O0J6XJN02I / Dutasteride
  •  go-up   go-down


43. Morozov AP, Trapeznikov MF, Kushlinskiĭ NE: [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):50-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protein of type 1 binding insulin-like growth factors in blood serum in cancer and prostatic adenoma].
  • We compared serum levels of insulin-like growth factors (IGF) type 1 protein (IGFP-1) in prostatic cancer (PC) and prostatic adenoma (PA).
  • Sensitivity and specificity of IGFP-1 estimation for differential diagnosis of PC were 72.1 and 57.1%, respectively), of IGFP-1/PSA for differential diagnosis was 81.3 and 87.5%, respectively.
  • [MeSH-major] Biomarkers, Tumor / blood. Insulin-Like Growth Factor Binding Protein 1 / blood. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580387.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin-Like Growth Factor Binding Protein 1; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


44. Seki N, Kai N, Seguchi H, Takei M, Yamaguchi A, Naito S: Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity. Urology; 2006 Feb;67(2):306-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictives regarding outcome after transurethral resection for prostatic adenoma associated with detrusor underactivity.
  • OBJECTIVES: To elucidate the predictive factors regarding the treatment outcomes after transurethral resection of the prostate for symptomatic benign prostatic enlargement with detrusor underactivity.
  • METHODS: A retrospective study was conducted in 190 patients with detrusor underactivity of 1397 men who had undergone transurethral resection of the prostate.
  • All patients had completed the International Prostate Symptom Score and quality-of-life (QOL) questionnaires and had undergone a full urodynamic analysis before surgery.
  • The outcomes were assessed at 3 and 12 months postoperatively using the International Prostate Symptom Score, QOL score, and peak urinary flow rate.
  • CONCLUSIONS: In selected patients with benign prostatic enlargement associated with detrusor underactivity, greater baseline storage symptom scores and the presence of DO were negative predictive factors for QOL improvement.
  • Baseline DO was also predictive of poorer improvement in the subjective symptoms after transurethral resection of the prostate.
  • [MeSH-major] Prostatic Hyperplasia / complications. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urinary Bladder Neck Obstruction / complications

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16461081.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Aliaev IuG, Apolikhin OI, Mazo EB, Vinarov AZ, Lokshin KL, Medvedev AA, Permiakova OV, Spivak LG, Shkol'nikov ME: [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations]. Urologiia; 2009 Jul-Aug;(4):36-40
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations].
  • The article presents 2-year pilot results of a multicenter, randomized, controlled trial of prostamol-UNO effects on symptoms progression, quality of life, tolerance and safety in patients with early prostatic adenoma.
  • Measurements were also made of changes in Qmax, urine volume, residual urine, size of the prostate.
  • [MeSH-major] Prostatic Hyperplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19824382.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 0 / Prostamol-Uno
  •  go-up   go-down


46. Al'-Shukri SKh, Gorbachev AG, Borovets SIu, Belousov VIa, Kuz'min IV, Chushkin KA: [Prostatilen treatment of prostatic adenoma]. Urologiia; 2006 Nov-Dec;(6):22, 25-6
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatilen treatment of prostatic adenoma].
  • We studied efficacy of repeated courses of prostatilen in suppositories with dimexide in prostatic adenoma patients with normal micturition.
  • This suggests possibility of suppository prostatilen use not only as an alternative for expensive drugs but also in combination with them in treatment of initial prostatic adenoma.
  • [MeSH-major] Peptides / therapeutic use. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17315707.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Peptides; 0 / Suppositories; 0 / prostatilen; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


47. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • Clinical variables were compared between patients with and without carcinoma involving the prostate using standard statistical software.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • There were 9 patients (26%) who had urothelial carcinoma involving the prostate; only prostatic urethral biopsy identified these patients before radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


48. Danilov VV, Vasil'chenko AV, Danilova TI, Besedin SA, Borshchenko SA, Danilov VV: [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma]. Urologiia; 2010 Nov-Dec;(6):16-9
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacourodynamic non-invasive studies in patients with prostatic adenoma].
  • After examination 47 patients with prostatic adenoma (mean age 63 years) received a course of alpha1-adenoblocker (omsulosin in a dose 0.4 mg/day).
  • Thus, long-term treatment with alpha1-adrenoblockers can be used as a pharmacourodynamic test to detect infravesical obstruction in patients with prostatic adenoma.
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Bladder Neck Obstruction / diagnosis. Urodynamics / drug effects

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427987.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


49. Shaplygin LV, Sivakov AA: [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 May-Jun;(3):35-7, 39
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of cernilton in the therapy of prostatic adenoma and chronic prostatitis].
  • A conservative therapy with cernilton was given to 72 patients with chronic prostatitis and prostatic adenoma of stage I-II.
  • Detailed urologic examination before the treatment and after it demonstrates that cernilton is effective, safe and well tolerated medicine for prostatic adenoma and chronic prostatitis.
  • Cernilton is recommended for wider use in the treatment of patients with prostatic adenoma and chronic prostatitis.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17722618.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


50. Danilov VV, Elisseva EV, Vasil'chenko AV: [Tadenan treatment of prostatic adenoma]. Urologiia; 2009 Mar-Apr;(2):68, 70-3
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tadenan treatment of prostatic adenoma].
  • Tadenan, a drug of plant origin, was given to 27 patients with documented prostatic adenoma for 3-12 months.
  • [MeSH-major] Plant Extracts / administration & dosage. Prostatic Hyperplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526878.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Fatty Alcohols; 0 / Plant Extracts; 0 / Tadenan
  •  go-up   go-down


51. Martella O, Galatioto GP, Pace G, Vicentini C: PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia. Arch Ital Urol Androl; 2010 Dec;82(4):139-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PSA supernormalisation: a surrogate of complete adenoma removal in men with benign prostatic hyperplasia.
  • It is known that serum prostate-specific antigen levels (PSA) decrease gradually following surgery for benign prostatic hyperplasia (BPH), but there is not an established cut-off value for normal PSA after relief of obstruction.
  • We evaluated the impact of prostatic adenoma enucleation on PSA levels in 110 patients who underwent transvesical suprapubic adenomectomy for symptomatic BPH.
  • We examined PSA levels before and after open surgery and weight of the prostatic adenoma as measured by the pathologist.
  • In patients with suspected abnormality on digital rectal examination or PSA > 4.0 ng/mL systematic multisite biopsies were performed preoperatively to rule out prostate cancer.
  • The mean weight of enucleated adenoma was 87 gr (range 50-201).
  • PSA supernormalisation represents an objective measure of complete adenoma removal.


52. Kamalov AA, Osmolovskiĭ BE: [Transurethral photoselective laser vaporization in the treatment of prostatic adenoma]. Urologiia; 2008 Sep-Oct;(5):28-31
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral photoselective laser vaporization in the treatment of prostatic adenoma].
  • Progress in laser technologies allowed development of a highly effective method of laser adenomectomy--photoselective vaporization of the prostate (PSVP).
  • [MeSH-major] Laser Therapy / instrumentation. Laser Therapy / methods. Prostatic Hyperplasia / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069492.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


53. Hojgaard M, Mikines KJ: Ureteral injuries during photoselective vaporization of the prostate. Scand J Urol Nephrol; 2010 Sep;44(4):265-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ureteral injuries during photoselective vaporization of the prostate.
  • Photoselective vaporization of the prostate is a relatively new surgical modality for male lower urinary tract symptoms.
  • The method has a risk of tissue damage if laser pulses miss the prostatic adenoma and travel through the irrigation fluid in the bladder.
  • Five cases of damage to the ureteral orifices are described, with hidden orifices, intravesical prostatic adenomas and prior prostatectomy as risk factors for laser-related injuries to ureteral orifices.
  • [MeSH-major] Laser Therapy / adverse effects. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / surgery. Ureter / injuries

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20201751.001).
  • [ISSN] 1651-2065
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


54. Boroian RR: [Growth factors in blood serum of patients with prostatic adenoma]. Urologiia; 2008 May-Jun;(3):41-4
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growth factors in blood serum of patients with prostatic adenoma].
  • A highly sensitive enzyme immunoassay has found that patients with prostatic adenoma aged 57-81 years have a higher concentration of the basic factor of growth of fibroblasts (bFGF) compared to controls (healthy males)--from 1.61 +/- 0.5 to 44.0 +/- 10.8 pg/ml while concentration of the transformation factor beta-1 is subnormal (19.1 +/- 2.2 to 3.5 +/- 1.2 pg/ml).
  • [MeSH-major] Fibroblast Growth Factor 2 / blood. Prostatic Hyperplasia / blood. Transforming Growth Factor beta1 / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669347.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta1; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


55. Markov AV, Luk'ianov IV, Loran OB: [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy]. Urologiia; 2007 Jul-Aug;(4):41-4
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complex therapy of irritative voiding disorders after transurethral resection of the prostate and adenomectomy].
  • Rehabilitation therapy was performed in 5 groups (n=122) of patients operated for prostatic adenoma (TUR of the prostate, transvesical prostatectomy) and having postoperative marked irritative miction disorders.
  • Thus, adjuvant physiotherapy inclusion in the complex of postoperative rehabilitation of patients operated for prostatic adenoma is justified as it improves treatment efficacy.
  • [MeSH-major] Prostatic Hyperplasia / rehabilitation. Urinary Incontinence / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy / methods. Follow-Up Studies. Humans. Male. Middle Aged. Prostate / surgery. Prostatectomy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915448.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


56. Aliaev IuG, Gadzhieva ZK, Petrovskiĭ NV: [Overactive bladder in patients with infravesical obstruction caused by prostatic adenoma]. Urologiia; 2010 Nov-Dec;(6):10-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overactive bladder in patients with infravesical obstruction caused by prostatic adenoma].
  • According to the literature, overactive bladder (OB) occurs in 52-80% men with infravesical obstruction (IVO) due to prostatic adenoma, 38% patients retain the disorder after surgical correction of the obstruction.
  • Urodynamic investigation of the lower urinary tract (LUT) function was conducted in 206 patients with prostatic adenoma admitted to the urological clinic of I.M.
  • This bladder dysfunction played a leading role in development of IVO complications (vesicoureteral reflux, ureterohydronephrosis) entailing marked disorder of the upper urinary tract disorder--chronic renal failure.
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Bladder Neck Obstruction / etiology. Urinary Bladder, Overactive / etiology

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Overactive Bladder.
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. PHENYLPROPANOLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21427986.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Antagonists; 0 / Benzhydryl Compounds; 0 / Cresols; 0 / Muscarinic Antagonists; 0 / Sulfonamides; 33RU150WUN / Phenylpropanolamine; 5T619TQR3R / Tolterodine Tartrate; G3P28OML5I / tamsulosin
  •  go-up   go-down


57. Cossu-Rocca P, Contini M, Brunelli M, Festa A, Pili F, Gobbo S, Eccher A, Mura A, Massarelli G, Martignoni G: S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma. Am J Surg Pathol; 2009 Jul;33(7):1031-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-100A1 is a reliable marker in distinguishing nephrogenic adenoma from prostatic adenocarcinoma.
  • Nephrogenic adenoma is a benign lesion that may occur at any site of the genitourinary tract, usually in association with previous urothelial injuries.
  • In addition to its uncertain origin, there can be diagnostic difficulty in distinguishing nephrogenic adenoma from prostatic adenocarcinoma, particularly with lesions arising in the prostatic urethra.
  • Alpha-methylacyl-CoA racemase (AMACR), a recently identified prostate cancer marker, has also been found to be expressed in renal tubules and in some renal epithelial neoplasms.
  • In this study, we investigated the expression of S100A1 and AMACR in 18 nephrogenic adenomas and in 100 prostatic adenocarcinomas.
  • A strong and distinct cytoplasmic or nucleocytoplasmic staining of S100A1 was found in 17 out of 18 cases of nephrogenic adenoma (94%), but never in prostatic adenocarcinoma.
  • In contrast, AMACR expression was detected in 14 of 18 nephrogenic adenomas (78%) and in 96 of 100 prostatic adenocarcinomas (96%).
  • We conclude that (1) S100A1 is a specific and sensitive immunohistochemical marker to differentiate nephrogenic adenoma from prostatic adenocarcinoma;.
  • (3) given that both S100A1 and AMACR have been reported to be expressed in renal tubular cells and in a subset of renal cell neoplasms, our findings confirm the histogenetic relationship between nephrogenic adenoma and renal tubular epithelium.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Prostatic Neoplasms / diagnosis. S100 Proteins / biosynthesis. Urogenital Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Racemases and Epimerases / biosynthesis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19384190.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins; 0 / S100A1 protein; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


58. Bogdanov AB, Luk'ianov IV, Veliev EI: [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):44-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
  • Clinical effects and safety of doxazosine + finasteride combination were studied in patients with obstructive and irritative symptoms due to prostatic adenoma (PA).
  • Lower urinary tract symptoms according to IPSS, size of the prostatic gland, Qmax and Qmid, bladder capacity, residual urine volume, blood pressure, PSA level, sexual function, side effects were assessed before and after combined use of the drugs in 30 patients aged 58 to 83 years (mean age 70.5 years).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatic Hyperplasia / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • Hazardous Substances Data Bank. FINASTERIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248599.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


59. Lopatkin NA, Petrov SB, Sivkov AV, Markov AV, Oshchepkov NN, Bolokhanov IuN: [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial]. Urologiia; 2006 May-Jun;(3):3-6, 8
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pilot results of using tamsulone-FS in patients with prostatic adenoma according to the results of a randomized multicenter comparative trial].
  • Tamsulone-FS--a novel Russian alpha1A/D-adrenoblocker (Farm-Syntez)--was studied in a randomized multicenter comparative trial in patients with prostatic adenoma.
  • Pilot results agreed with other trials published in the literature and demonstrated tamsulone-FS efficacy and safety for management of lower urinary tract symptoms caused by prostatic adenoma.
  • This drug can be recommended for wide clinical practice in prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Antineoplastic Agents / therapeutic use. Prostatic Hyperplasia / drug therapy. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889080.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


60. Teodorovich OV, Zabrodina NB, Bochkarev AB: [Using setegis (terasosine) in early postoperative period after transurethral prostate resection]. Urologiia; 2009 May-Jun;(3):62-4
Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Using setegis (terasosine) in early postoperative period after transurethral prostate resection].
  • TUR of the prostatic gland for prostatic adenoma was made in 93 patients aged 54-81 years (mean age 64.4 +/- 7.5 years).
  • Thus, terasosine (setegis) can be recommended for use in early postoperative period after TUR of the prostate for prostatic adenoma as an effective and safe drug improving postoperative outcome.
  • [MeSH-major] Adrenergic alpha-Antagonists / therapeutic use. Prazosin / analogs & derivatives. Prostatic Hyperplasia / drug therapy. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate. Urination Disorders / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673124.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 8L5014XET7 / Terazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


61. Pushkar' DIu, Loran OB, Petrov SB, Kogan MI, Zhuravlev VN: [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial]. Urologiia; 2008 Jan-Feb;(1):23, 25-6
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy and safety of revocarin in patients with impaired micturition due to prostatic adenoma. An open non-comparative study: results of a multicenter trial].
  • Patients with impaired micturition caused by prostatic adenoma received revocarin for 12-weeks.
  • Thus, a 12-week course of revocarin demonstrated good clinical efficacy and safety in patients with urination problems because of prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage. Urinary Retention / drug therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18649675.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


62. Aslamazov EG, Akhvlediani ND, Vinarov AZ, Aliaev IuG: [Cernilton in the treatment of prostatic adenoma and chronic prostatitis]. Urologiia; 2007 Jan-Feb;(1):52, 54-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cernilton in the treatment of prostatic adenoma and chronic prostatitis].
  • The efficacy of the drug cernilton was studied in patients with prostatic adenoma (PA) and chronic bacterial prostatitis (CBP).
  • [MeSH-major] Plant Extracts / therapeutic use. Prostatic Hyperplasia / drug therapy. Prostatitis / drug therapy

  • Genetic Alliance. consumer health - Prostatitis.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472001.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Plant Extracts; 8054-43-1 / cernilton
  •  go-up   go-down


63. Davidov MI: [Factors predisposing to acute urine retention in patients with prostatic adenoma]. Urologiia; 2007 Mar-Apr;(2):25-31
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors predisposing to acute urine retention in patients with prostatic adenoma].
  • The aim of the trial was to study factors predisposing to acute urine retention (AUR) in patients with prostatic adenoma (PA).
  • [MeSH-major] Prostatic Hyperplasia / complications. Urinary Retention / epidemiology. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17580384.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


64. Desai MM, Fareed K, Berger AK, Astigueta JC, Irwin BH, Aron M, Ulchaker J, Sotelo R: Single-port transvesical enucleation of the prostate: a clinical report of 34 cases. BJU Int; 2010 May;105(9):1296-300
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-port transvesical enucleation of the prostate: a clinical report of 34 cases.
  • OBJECTIVE: To present our experience with single-port transvesical enucleation of the prostate (STEP) in 34 patients with large-volume benign prostatic hyperplasia (BPH).
  • The mean prostate volume estimated by transrectal ultrasonography was 102.5 mL and the mean baseline prostate-specific antigen level was 6.7 ng/mL.
  • After establishing pneumovesicum, the prostate adenoma was enucleated transvesically using standard laparoscopic instruments, and the adenoma was extracted in pieces through the port.
  • Digital assistance expedited enucleation of the apical adenoma in 19 (55%) cases.
  • Under pneumovesicum using laparoscopic visualization, the entire adenoma can be effectively enucleated and expeditiously extracted through the novel single port.
  • [MeSH-major] Laparoscopy. Laser Therapy / methods. Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery. Robotics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20346053.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


65. Prada Gómez PJ, de la Rua Calderón A, Romo Fonseca I, Evia Suárez M, Abascal García JM, Juan Rijo G, Fernández García J, González Sancho JM, Abascal García R, Rodríguez-Fernández R: High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience. Clin Transl Oncol; 2005 Oct;7(9):389-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose brachytherapy (real time) in patients with intermediate- or high-risk prostate cancer: technical description and preliminary experience.
  • INTRODUCTION: It has been well documented that the outcome of prostate cancer treatment depends on the dose administered.
  • Between June 1998 and December 2004, 100 patients with adenoma of the prostate were treated with 46 Gy of external irradiation to the pelvis and 2 HDR brachytherapy fractions (each of 1150 cGy) at the end of weeks 1 and 3 of a 5-week radiotherapy course.
  • CONCLUSIONS: The good results of local control, disease-free survival and few complications that the external radiotherapy combined with HDR brachytherapy have shown suggest that the method should be considered as first-choice in the treatment of prostate tumours of high- and intermediate-risk.
  • [MeSH-major] Brachytherapy / methods. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Disease-Free Survival. Follow-Up Studies. Humans. Male. Postoperative Complications. Prostate / pathology. Prostate / radiation effects. Prostate / surgery. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238973.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


66. Byun SS, Jeong H, Jo MK, Lee E: Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men? Urology; 2005 Sep;66(3):593-6
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relative proportions of tissue components in the prostate: are they related to the development of symptomatic BPH in Korean men?
  • OBJECTIVES: To investigate the high prevalence of lower urinary tract symptoms in Korean men with a small prostate, we studied the proportions of histologic components of prostatic adenoma in patients with symptomatic benign prostatic hyperplasia.
  • METHODS: Prostatic adenoma specimens were obtained from men with symptomatic benign prostatic hyperplasia who underwent open prostatectomy or transurethral resection of the prostate.
  • Patients were divided into three groups according to the prostate volume as measured by preoperative transrectal ultrasonography (group 1, 20 to 40 cm3, 21 men; group 2, 41 to 80 cm3, 22 men; and group 3, greater than 80 cm3, 23 men).
  • The proportion of the stroma in the prostatic adenoma and the proportions of smooth muscle, collagen types I, II, III, and V, fibronectin, and laminin in stromal tissue were determined using automatic image analyzer quantitatively.
  • RESULTS: The proportions of the stroma in the prostatic adenoma specimens of groups 1 and 2 were significantly greater than in group 3 (P < 0.05).
  • The relative smooth muscle proportion in the prostatic adenoma (proportion of stroma x proportion of smooth muscle in stromal tissue) in groups 1 and 2 was significantly greater than in group 3 (P < 0.05).
  • CONCLUSIONS: These results suggest that the dynamic component of bladder outlet obstruction, which is mediated by smooth muscle tone, may play a more important role in the development of symptomatic benign prostatic hyperplasia in Korean men.
  • [MeSH-major] Prostatic Hyperplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140084.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Modi P, Helfand BT, McVary KT: Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen. Curr Urol Rep; 2010 Jul;11(4):224-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.
  • Prostate-specific antigen (PSA) is the most widely used marker for prostate cancer (CaP) screening and monitoring benign prostatic hyperplasia (BPH) progression.
  • However, lack of an established abnormal threshold and the presence of other benign processes confound the interpretation of PSA levels.
  • For example, the commonly used 5 alpha reductase inhibitor (5ARI) medications directly affect PSA levels by decreasing prostate volume.
  • The amount of time and potentially even the 5ARI formulary a patient is administered has been implicated to directly impact the degree of reduction in PSA (a proxy for prostate volume).
  • In addition, each of the currently available surgical procedures for BPH appears to remove varying amounts of prostatic adenoma.
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / therapy


68. Lepage JY, Rivault O, Karam G, Malinovsky JM, Le Gouedec G, Cozian A, Malinge M, Pinaud M: [Anaesthesia and prostate surgery]. Ann Fr Anesth Reanim; 2005 Apr;24(4):397-411
MedlinePlus Health Information. consumer health - Anesthesia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaesthesia and prostate surgery].
  • [Transliterated title] Anesthésie et chirurgie de la prostate.
  • OBJECTIVES: To review the current data about anaesthetic management in prostate surgery with special regards on analysis and prevention of specific risks, appropriate anaesthetic procedure keeping with surgery and patient, recognition and treatment of adverse events.
  • Preoperative evaluation of cardiovascular, respiratory, neurological and metabolic comorbidity is a source of prognostic information and an essential tool in the management of elderly patients with prostate disease.
  • Extreme patient positioning applied in prostate surgery induces haemodynamic and respiratory changes and are associated with severe muscular and nervous injuries.
  • Whether open transvesical or transurethral prostatectomy for treatment of benign hypertrophy depends on the size of the gland: transurethral resection is safe up to 80 g.
  • Intrathecal anaesthesia with a T9 cephalad spread of sensory block, produces adequate conditions for transurethral prostatectomy and allows a rapid diagnosis of irrigating fluid absorption syndrome.
  • In spite of recommended preoperative antibiotic prophylaxis, bacteriemias are frequent during transurethral prostate resection.
  • [MeSH-major] Anesthesia. Prostate / surgery. Urogenital Surgical Procedures
  • [MeSH-minor] Adenoma / surgery. Humans. Intraoperative Complications / epidemiology. Intraoperative Complications / prevention & control. Male. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Preoperative Care. Prostatectomy / adverse effects. Prostatic Neoplasms / surgery. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15826790.001).
  • [ISSN] 0750-7658
  • [Journal-full-title] Annales françaises d'anesthèsie et de rèanimation
  • [ISO-abbreviation] Ann Fr Anesth Reanim
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 186
  •  go-up   go-down


69. Hawtrey CE, Williams RD: Historical evolution of transurethral resection at the University of Iowa: Alcock and Flocks. J Urol; 2008 Jul;180(1):55-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alcock proclaimed that transurethral resection of the prostate "...cannot be taught and can be learned only by hard, tedious experience."
  • Flocks, added basic science and anatomical knowledge to Alcock's surgical experience to create a body of work that even today provides insight into the complexities of transurethral prostatic resection.
  • MATERIALS AND METHODS: Even as Alcock studied preoperative and postoperative urethrography images to provide demonstration of the enlarged prostate, he firmly believed in the learning curve of surgical proficiency.
  • However, when Alcock and Flocks began studying autopsy material they were able to pinpoint distribution of the prostatic blood supply, and demonstrate techniques to control bleeding and perform transurethral resection in an organized fashion.
  • RESULTS: In his 1932 report to the American Urological Association Alcock detailed not only his surgical success, but also his mortality rate related to resection and prostatic obstruction and its complications.
  • In autopsy specimens with barium sulfate injections into prostatic blood vessels Flocks demonstrated that complete resection of prostate adenoma was possible and produced the desired outcome with good wound healing.
  • CONCLUSIONS: The strong collaboration between Alcock and Flocks, particularly during the 1940s, culminated in a movie presentation of the prostatic resection technique as viewed from inside the bladder antegrade toward the prostate that remains a model for surgical practice today.
  • [MeSH-major] Transurethral Resection of Prostate / history

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2008 Jul;180(1):15-6 [18485411.001]
  • (PMID = 18485410.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Personal-name-as-subject] Alcock NG; Flocks RH
  •  go-up   go-down


70. Sevriukov FA, Puchkin AB, Krupin VN, Chebykin AV, Sorokin DA, Karpukhin IV, Malinina OIu, Zorin DG: [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases]. Urologiia; 2007 May-Jun;(3):28-32, 35
MedlinePlus Health Information. consumer health - Prostate Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transurethral electrosurgery of a new generation (TURis) in the treatment of the lower urinary tract and prostate diseases].
  • Surgical interventions were made in 175 patients aged 23-87 years (mean age 64.8 years) with different diseases of the lower urinary tract (adenoma, prostatic cancer, cancer of the urinary bladder, etc.) with application of a new generation of endoscopic technique--transurethral resection in saline (TURis system) with a generator UES-40 SurgMaster (Olympus).
  • The size of the prostate in prostatic adenoma ranged from 4.8 to 121 cm3 (mean 62.5 cm3), residual urine--92.3 ml (42.6 to 310.2 ml).
  • Mean amount of the resected tissue in sclerosis of urinary bladder cervix was 7 g (5-11 g), in prostatic adenoma--41 g (10-85 g), prostatic cancer--27 g (17-49 g).
  • Incontinence was observed in 7 (5.3%) patients after removal of urethral catheter, in 5 (3.8%) patients it stopped spontaneously to the time of discharge from the hospital, 2 (1.5%) patients with prostatic cancer retained partial orthostatic incontinence.
  • Standard time limitation for transurethral resection (60-90 min) becomes insignificant in using isotonic irrigation allowing urologists to resect safely larger adenomas than it was possible earlier.
  • [MeSH-major] Electrosurgery / methods. Prostatic Diseases / surgery. Urinary Tract / surgery. Urologic Diseases / surgery. Urologic Surgical Procedures, Male / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Transurethral Resection of Prostate / instrumentation. Transurethral Resection of Prostate / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724828.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


71. Boroian RR: [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma]. Urologiia; 2008 Nov-Dec;(6):49-52
Hazardous Substances Data Bank. FINASTERIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basic fibroblast growth factor as a prognostic factor of medication efficacy by meanes of prostatic adenoma].
  • To determine prognostic factors of lower urinary tract symptoms progression because of prostatic adenoma (PA), we studied content of the basic fibroblast growth factor (bFGF) in blood serum of patients with PA in enzyme immunoassay.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Enzyme Inhibitors / administration & dosage. Fibroblast Growth Factor 2 / blood. Finasteride / administration & dosage. Prostatic Hyperplasia / blood. Prostatic Hyperplasia / drug therapy. Sulfonamides / administration & dosage

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. Tamsulosin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19248600.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 103107-01-3 / Fibroblast Growth Factor 2; 57GNO57U7G / Finasteride; G3P28OML5I / tamsulosin
  •  go-up   go-down


72. Cabello Benavente R, Jara Rascón J, Monzó JI, López Díez I, Subirá Ríos D, Lledó García E, Herranz Amo F, Hernández Fernández C: [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen]. Actas Urol Esp; 2006 Feb;30(2):175-80
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Volume determinations of the whole prostate and of the adenoma by transrectal ultrasound: correlation with surgical specimen].
  • [Transliterated title] Correlación ecográfico-anatómica de la medición del volumen prostático total y de la zona transicional mediante ecografía transrectal.
  • OBJECTIVE: We evaluated whether preoperative transrecta ultrasound (TRUS) mesaurements of the transition zone (TZ) and total prostate volumen predict real prostatic weight.
  • MATERIAL AND METHODS: We compare estimated TRUS volumes with surgical specimen weight, in surgically treated patients with localized prostate cancer (group A, n = 33) or benign prostatic hyperplasia (group B, n = 37).
  • Both measurements were compared with surgical specimen weight, assuming 1 as specific prostate weight.
  • RESULTS: Group A: mean prostate measured volume was 38.6 cc. (SD 22.7), mean RP specimen weight was 54,2 g (SD 27.2) (p = 0.001).
  • Total estimated prostate volume underestimated prostatectomy specimen weight by 29%.
  • In order to adequate the estimated volume to the specimen weight, we calculated the formula: estimated prostate weight = 0.95 x prostatic measured volume + 17,657 (p = 0.005).
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / ultrasonography. Prostatic Neoplasms / pathology. Prostatic Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700208.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


73. Hiraoka Y, Shimizu Y, Iwamoto K, Takahashi H, Abe H: Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate. Urol Int; 2007;79(1):50-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trial of complete detachment of the whole prostate lobes in benign prostate hyperplasia by transurethral enucleation of the prostate.
  • INTRODUCTION: We tried a complete detachment of the whole prostate lobes for benign prostate hyperplasia (BPH) by transurethral enucleation of the prostate (TUE).
  • MATERIALS AND METHODS: For 46 BPH cases the whole prostate lobes were detached from the surgical capsule completely by a prostate-detaching blade and resectoscope beak, and dropped into the bladder.
  • The detached prostate lobes were removed by a soft tissue morcellator.
  • The preoperative total prostate and adenoma volume by transabdominal ultrasound measurement (TAUS) were 47.75 +/- 25.63 and 27.8 +/- 17.33 ml.
  • RESULTS: In all 46 BPH cases, the whole prostate lobes could be detached completely without a perforation.
  • Postoperative prostate volume and PSA were decreased to 9.56 ml and 0.8 ng/ml with complete removal of an adenoma.
  • CONCLUSIONS: TUDP could achieve complete removal of even a large adenoma without perforation, transurethral resection syndromes and blood transfusion safety.
  • [MeSH-major] Prostate / surgery. Prostatectomy / methods. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17627169.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


74. Tarasov NI, Izmaĭlov RI: [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride]. Urologiia; 2009 Sep-Oct;(5):40-5
Hazardous Substances Data Bank. FINASTERIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of combined treatment of large prostatic adenoma with doxasozine and finasteride].
  • Combined treatment with doxasozine and finasteride was performed for 7.26 months in 38 patients with large-size prostatic adenoma (89.54 +/- 11.64 cm3).
  • The control group (28 patients with large prostatic adenoma) received surgical treatment alone.
  • Thus, combined treatment with doxasozine and finasteride can be the first-line treatment in patients with large prostatic adenoma.
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Doxazosin / administration & dosage. Enzyme Inhibitors / administration & dosage. Finasteride / administration & dosage. Prostatectomy. Prostatic Hyperplasia / therapy

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209869.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Enzyme Inhibitors; 57GNO57U7G / Finasteride; NW1291F1W8 / Doxazosin
  •  go-up   go-down


75. Fromont G, Barcat L, Gaudin J, Irani J: Revisiting the immunophenotype of nephrogenic adenoma. Am J Surg Pathol; 2009 Nov;33(11):1654-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting the immunophenotype of nephrogenic adenoma.
  • Nephrogenic adenoma (NA) is a rare benign lesion of the urinary tract.
  • As NA can be difficult to distinguish from malignant conditions such as prostate cancer, there is a need for reliable markers.
  • Unfortunately, it has been reported that NA cells also stained positive for the prostate cancer marker alpha-methylacyl-coenzyme A racemase (AMACR).
  • The tissue microarray also included renal, urothelial, and prostate tissues.
  • These findings provide supporting evidence that NA has the differentiation of distal renal tubules, and strongly suggest that AMACR, when detected with a biotin-free procedure, can be used as a reliable marker for distinguishing NA from prostate cancer.
  • [MeSH-major] Adenoma / immunology. Immunophenotyping / methods. Urologic Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Child. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Indirect. Humans. Kidney Tubules / enzymology. Male. Middle Aged. Prostatic Neoplasms / diagnosis. Racemases and Epimerases / metabolism. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19730362.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


76. Trapeznikova MF, Pozdniakov KV, Golubev GV, Terpigorev SA, Agel'tsov MV, Kuznetsov VE, Shvedov MIu: [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease]. Urologiia; 2009 Jan-Feb;(1):35-40
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current trends in pharmacotherapy of prostatic adenoma: role of a new alpha-adrenoblocker kamiren XL in the treatment of this disease].
  • The aim of our study was assessment of clinical efficacy and safety of a new alpha-adrenoblocker kamiren XL in patients with prostatic adenoma (PA) with or without acute retention of urine (ARU).
  • [MeSH-major] Adrenergic alpha-Antagonists / administration & dosage. Prostatic Hyperplasia / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434906.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists
  •  go-up   go-down


77. Shimizu Y, Hiraoka Y, Iwamoto K, Takahashi H, Abe H: Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique. Urol Int; 2005;74(2):102-7
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of residual adenoma after transurethral resection of the prostate by transurethral enucleation technique.
  • OBJECTIVE: Transurethral resection of the prostate (TURP) leaves a lot of residual adenoma and has a high recurrence rate, but the residual adenoma weight has not been measured surgically.
  • Using surgery we tried to measure the residual adenoma after TURP.
  • MATERIAL AND METHODS: Total adenoma resection was performed via standard TURP in 64 cases with benign prostatic hyperplasia and the weight of the residual adenoma was measured by transurethral enucleation (TUE) of the prostate.
  • RESULTS: Prostate volume averaged 37.4 ml and adenoma volume averaged 20.6 ml by TRUS.
  • The average weight of the prostate removed by TURP was 9.8 g.
  • After TURP residual adenoma was confirmed in all cases by TUE, and the average weight of the residual adenoma was 10.2 g.
  • The total average prostate volume removed by TURP and TUE was 20.1 g.
  • The average residual rate of the adenoma removed by TURP was 54.5%.
  • CONCLUSION: TURP leaves about half of the adenoma.
  • Therefore, TURP might be very difficult for complete resection of an adenoma.
  • [MeSH-major] Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756059.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


78. Weissbach L, Ebert T, Schmitz-Dräger B: [Taking stock after 400 days: the effects on ambulatory care from a medical point of view]. Z Arztl Fortbild Qualitatssich; 2006;100(1):40-3; discussion 44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taking the contract signed with the AOK Bavaria and comprising the integrated care of patients with prostate carcinoma, prostate adenoma and prostatitis as an example the contents and consequences of this agreement will be described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524229.001).
  • [ISSN] 1431-7621
  • [Journal-full-title] Zeitschrift für ärztliche Fortbildung und Qualitätssicherung
  • [ISO-abbreviation] Z Arztl Fortbild Qualitatssich
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Pushkar' DIu, belousov IuB, Dukhanin AS, Maneshina OA, Govorov AV, Kurdzhiev MA: [Interaction of omnic (tamsulozine) and its generic analogues with alpha-adrenoreceptors]. Urologiia; 2009 Sep-Oct;(5):36-40
Hazardous Substances Data Bank. Tamsulosin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In current practice of pharmacotherapy of prostatic adenoma alpha1-adrenoblockers are first-line drugs the efficacy and safety of which have been proved in many randomized studies.
  • Because of the appearance of a large amount of generic analogues of tamsulozine on the market we studied the ability of tamsulozine analogues to bind with alpha-adrenoreceptors on rat and human prostate affected by adenoma.
  • [MeSH-major] Adenoma / metabolism. Adenoma / microbiology. Adrenergic alpha-Antagonists / pharmacokinetics. Drugs, Generic / pharmacokinetics. Prostate / metabolism. Receptors, Adrenergic, alpha / metabolism. Sulfonamides / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20209868.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Drugs, Generic; 0 / Receptors, Adrenergic, alpha; 0 / Sulfonamides; G3P28OML5I / tamsulosin
  •  go-up   go-down


80. Sung W, Park BD, Lee S, Chang SG: Villous adenoma of the urinary bladder. Int J Urol; 2008 Jun;15(6):551-3
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villous adenoma of the urinary bladder.
  • Villous adenomas arising in the urinary tract are an uncommon occurrence.
  • They have been identified in the urachus, urethra, prostate, and throughout the bladder.
  • Villous adenomas arising in the bladder are rare tumors that have been described as isolated cases and a few case series.
  • We report a new case of a large villous adenoma arising in the bladder that was treated by transurethral resection.
  • [MeSH-major] Adenoma, Villous / diagnosis. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489648.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


81. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, Hou LF, Berndt SI, Yadavalli S, Johnson CC, Hayes RB: Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev; 2005 Jan;14(1):152-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma.
  • Cigarette smoking is a risk factor for colorectal adenoma, a precursor of colorectal cancer.
  • Among participants randomized to the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, we evaluated risks for advanced adenoma in relation to cigarette use and these two EPHX1 variants.
  • We compared 772 cases with advanced adenoma (adenoma >/=1 cm or containing high-grade dysplasia or villous, including tubulovillous, elements) of the distal colon (left-sided, descending colon and sigmoid or rectum) to 777 gender- and age-matched controls who were screen-negative for left-sided adenoma.
  • Compared to those with homozygous genotypes predicting low EPHX1 activity, advanced adenoma risks tended to be elevated for carriers of (113)TyrTyr [odds ratios (OR), 1.5; 95% confidence intervals (CI), 1.0-2.2] and (139)ArgArg (OR, 1.4; 95% CI, 0.8-2.5) and for subjects who carried a greater number of the alleles ((113)Tyr or (139)Arg) associated with high predicted enzymatic activity (P(trend) = 0.03).
  • In conclusion, EPHX1 variants at codon 113 and 139 associated with high predicted enzymatic activity appear to increase risk for colorectal adenoma, particularly among recent and current smokers.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Epoxide Hydrolases / genetics. Polymorphism, Genetic. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Coriell Cell Repositories. culture/stock collections - Coriell Cell Repositories .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668489.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.3.2.- / Epoxide Hydrolases
  •  go-up   go-down


82. Peters U, Chatterjee N, Hayes RB, Schoen RE, Wang Y, Chanock SJ, Foster CB: Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma. Cancer Epidemiol Biomarkers Prev; 2008 May;17(5):1144-54
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variation in the selenoenzyme genes and risk of advanced distal colorectal adenoma.
  • We therefore investigated whether genetic variants in selenoenzymes abundantly expressed in the colon are associated with advanced colorectal adenoma, a cancer precursor.
  • METHODS: Cases with a left-sided advanced adenoma (n = 772) and matched controls (n = 777) screen negative for polyps based on sigmoidoscopy examination were randomly selected from participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
  • RESULTS: Four variants in SEPP1 were significantly associated with advanced adenoma risk.
  • Three SNPs located in the 3' region of SEPP1, which is overlapping with the promoter region of an antisense transcript, were significantly associated with adenoma risk: homozygotes at two SEPP1 loci (31,174 bp 3' of STP A>G and 43,881 bp 3' of STP G>A) were associated with increased adenoma risk [odds ratio (OR), 1.48; 95% confidence interval (95% CI), 1.00-2.19 and OR, 1.53; 95% CI, 1.05-2.22, respectively] and the variant SEPP1 44,321 bp 3' of STP C>T was associated with a reduced adenoma risk (CT versus CC OR, 0.85; 95% CI, 0.63-1.15).
  • Furthermore, we observed a significant 80% reduction for advanced colorectal adenoma risk for carriers of the variant allele at TXNRD1 IVS1-181C>G (OR, 0.20; 95% CI, 0.07-0.55; P trend = 0.004).
  • Consistent with the individual SNP results, we observed a significant overall association with adenoma risk for SEPP1 and TXNRD1 (global P = 0.02 and 0.008, respectively) but not for the four GPX genes.
  • CONCLUSION: Our study suggests that genetic variants at or near the SEPP1 and TXNRD1 loci may be associated with advanced colorectal adenoma.
  • [MeSH-major] Adenoma / enzymology. Adenoma / genetics. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Genetic Variation. Selenium

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18483336.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Selenoprotein P; EC 1.11.1.- / GPX2 protein, human; EC 1.11.1.- / GPX3 protein, human; EC 1.11.1.- / glutathione peroxidase GPX1; EC 1.11.1.12 / phospholipid-hydroperoxide glutathione peroxidase; EC 1.11.1.9 / Glutathione Peroxidase; EC 1.8.1.9 / TXNRD1 protein, human; EC 1.8.1.9 / Thioredoxin Reductase 1; H6241UJ22B / Selenium
  •  go-up   go-down


83. Tinmouth WW, Habib E, Kim SC, Kuo RL, Paterson RF, Terry CL, Elhilali M, Lingeman JE: Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection? J Endourol; 2005 Jun;19(5):550-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Change in serum prostate specific antigen concentration after holmium laser enucleation of the prostate: a marker for completeness of adenoma resection?
  • BACKGROUND AND PURPOSE: Holmium laser enucleation of the prostate (HoLEP) is a well-established technique for the treatment of benign prostatic hyperplasia (BPH).
  • To date, changes in serum prostate specific antigen (PSA) after HoLEP have not been published.
  • Change in PSA as a function of the weight of prostate resected and the relation of preoperative TRUS volume to PSA was determined.
  • RESULTS: The average weight of adenoma resected was 49.8 g (range 5-300 g) in the McGill group and 90.4 g (range 7.9-312 g) in the Methodist Hospital group.
  • Log transformed preoperative PSA correlated well with TRUS volume (r = 0.45), as did the weight of adenoma resected with absolute change in PSA (r = 0.38).
  • CONCLUSION: The HoLEP procedure produces a significant diminution in PSA that correlates well with the weight of adenoma resected.
  • Measurement of PSA may be a useful tool for the objective assessment of ablative therapies for BPH, as the reduction in PSA corresponds well with the amount of adenoma removed.


84. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol; 2006 Mar;13(3):303-4
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
  • Gonadotropin-releasing hormone (GnRH) agonists have become the treatment of choice for locally advanced and metastatic prostate cancer.
  • We report a case of prostate cancer in which this treatment led to severe symptoms of intracranial hypertension due to the concomitant presence of an asymptomatic functional pituitary adenoma.
  • The histopathological examination revealed an invasive gonadotroph pituitary adenoma.
  • Two years later, there is no sign of progression either on his prostatic disease (prostate-specific antigen of 0.21 ng/mL) or on his pituitary disease (FSH, 4.7 UI/L, LH, 3.1 UI/L and total testosterone, 627 ng/dL) with values of the hypothalamic-pituitary axis in the normal range.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / diagnosis. Antineoplastic Agents, Hormonal / therapeutic use. Gonadotropin-Releasing Hormone / agonists. Leuprolide / therapeutic use. Neoplasms, Multiple Primary. Pituitary Neoplasms / diagnosis. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643633.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


85. Tunici P, Yu JS: Pituitary adenoma stem cells. Methods Mol Biol; 2009;568:195-201
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenoma stem cells.
  • Reports have been published on the identification of tumor cells with stem cells characteristics in different types of tumors (acute myelogenic leukemia, breast cancer, prostate cancer, bone sarcomas, liver cancer, and melanomas).
  • More recently we have isolated tumor stem-like cells also from benign tumors like pituitary adenomas.
  • Cells derived from pituitary adenomas are able to grow as floating aggregates resembling the neurospheres (typical of normal stem cells) in a medium supplemented by growth factors (EGF and bFGF).
  • In vitro tumor stem-like cells derived from a patient with a somatotroph adenoma showed high production of growth hormone and prolactin, while cells derived from the same patient but grown in presence of fetal bovine serum showed no production of hormones.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582428.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


86. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol; 2006 Jan;13(1):87-8
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
  • We report the case of a T3 prostate cancer in a 70-year-old white man.
  • Hormone therapy represents a prominent branch in the treatment of locally advanced and metastatic prostate cancer.
  • This phenomenon may be noxious in the case of gonadotroph adenoma, with subsequent symptoms of intracranial hypertension.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Leuprolide / adverse effects. Pituitary Neoplasms / chemically induced. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448441.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


87. Hou L, Chatterjee N, Huang WY, Baccarelli A, Yadavalli S, Yeager M, Bresalier RS, Chanock SJ, Caporaso NE, Ji BT, Weissfeld JL, Hayes RB: CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma. Carcinogenesis; 2005 Jun;26(6):1122-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYP1A1 Val462 and NQO1 Ser187 polymorphisms, cigarette use, and risk for colorectal adenoma.
  • Cigarette use is a risk factor for colorectal adenoma, a known precursor of colorectal cancer.
  • We investigated the association of cigarette smoking with risk for advanced colorectal adenoma in relation to the CYP1A1 Val(462) and NQO1 Ser(187) polymorphic variants.
  • Subjects were 725 non-Hispanic Caucasian cases with advanced colorectal adenoma of the distal colon (descending colon, sigmoid and rectum) and 729 gender- and ethnicity-matched controls, randomly selected from participants in the prostate, lung, colorectal and ovarian cancer screening trial.
  • Subjects carrying either CYP1A1 Val(462) or NQO1 Ser(187) alleles were weakly associated with risk of colorectal adenoma; however, subjects carrying both CYP1A1 Val(462) and NQO1 Ser(187) alleles showed increased risks (OR = 2.2, 95% CI = 1.1-4.5), particularly among recent (including current) (OR = 17.4, 95% CI = 3.8-79.8, P for interaction = 0.02) and heavy cigarette smokers (>20 cigarettes/day) (OR = 21.1, 95% CI = 3.9-114.4, P for interaction = 0.03) compared with non-smokers who did not carry either of these variants.
  • In analysis of adenoma subtypes, the combined gene variants were most strongly associated with the presence of multiple adenoma (P = 0.002).
  • In summary, joint carriage of CYP1A1 Val(462) and NQO1 Ser(187) alleles, particularly in smokers, was related to colorectal adenoma risk, with a propensity for formation of multiple lesions.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Cytochrome P-450 CYP1A1 / genetics. NAD(P)H Dehydrogenase (Quinone) / genetics. Polymorphism, Genetic. Smoking / adverse effects

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15731166.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human
  •  go-up   go-down


88. Tong GX, Melamed J, Mansukhani M, Memeo L, Hernandez O, Deng FM, Chiriboga L, Waisman J: PAX2: a reliable marker for nephrogenic adenoma. Mod Pathol; 2006 Mar;19(3):356-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2: a reliable marker for nephrogenic adenoma.
  • Nephrogenic adenoma is a rare lesion of the urinary tract.
  • The diagnosis usually is straightforward when characteristic microscopic and clinical findings are present, and the entity is familiar.
  • However, misdiagnosis, in particular of adenocarcinoma of the prostate gland, may occur.
  • It recently was demonstrated that nephrogenic adenoma in renal transplant patients originated from the renal tubular epithelium.
  • This newly proved, but long sought information may be helpful in the differential diagnosis of nephrogenic adenoma.
  • In this study, we investigated the expression of a renal transcription factor, PAX2, in 39 nonrenal transplant-related nephrogenic adenomas, 100 adenocarcinomas of the prostate gland, and 47 urothelial carcinomas of the urinary tract.
  • A strong and distinct nuclear staining of PAX2 was found in all 39 cases of nephrogenic adenoma (100%), but not in normal prostate tissue, normal urothelium, adenocarcinomas of the prostate gland, and invasive urothelial carcinomas.
  • Focal CD10 was detected in six of 13 nephrogenic adenomas in the superficial papillary component and in normal prostate epithelium, normal urothelium, lymphocytes, adenocarcinoma of the prostate gland, and urothelial carcinoma.
  • There was no uroplakins detected in nephrogenic adenoma.
  • Therefore, these findings are suggesting that nephrogenic adenoma in nonrenal transplant patients may also arise from the renal epithelium, as did the comparable lesions after transplantation.
  • PAX2 is a specific and sensitive immunohistochemical marker in identification and differential diagnosis of nephrogenic adenoma.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. PAX2 Transcription Factor / analysis. Urologic Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. Male. Middle Aged. Neprilysin / analysis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400326.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; 68238-35-7 / Keratins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


89. Helfand BT, Anderson CB, Fought A, Kim DY, Vyas A, McVary KT: Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology; 2009 Jul;74(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
  • OBJECTIVES: To determine whether prostate-specific antigen (PSA) values can distinguish those with prostate cancer (CaP) from those with histologic benign prostatic hyperplasia (BPH) only after surgical intervention.
  • Prostatic adenoma inevitably remains after BPH surgery; therefore, patients remain at risk of developing CaP.
  • METHODS: We performed a review of patients who had undergone transurethral resection of the prostate (TURP; n = 343), holmium laser resection of the prostate (HoLRP; n = 54), or open prostatectomy (OP; n = 68).
  • [MeSH-major] Prostate-Specific Antigen / blood. Prostatectomy. Prostatic Hyperplasia / surgery. Prostatic Neoplasms / blood. Prostatic Neoplasms / diagnosis


90. Alivizatos G, Skolarikos A, Chalikopoulos D, Papachristou C, Sopilidis O, Dellis A, Kastriotis I, Deliveliotis C: Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas &gt;80ml: 12-mo results of a randomized prospective study. Eur Urol; 2008 Aug;54(2):427-37
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study.
  • OBJECTIVES: To compare the effectiveness and the safety of photoselective vaporization of the prostate (PVP) to open prostatectomy (OP) for the surgical treatment of large prostatic adenomas.
  • METHODS: A total of 125 patients with prostate glands >80ml were randomly allocated to PVP (n=65) or OP (n=60) and prospectively evaluated at 1, 3, 6, and 12 mo postoperatively.
  • International Prostate Symptom Score (IPSS) and peak urinary flow rate (Q(max)) were chosen as primary treatment-related end points.
  • At 3 mo prostate volume was significantly lower in the OP group compared to the PVP group (median value 10ml vs. 50ml; p<0.001) and remained as such throughout follow-up, whereas prostate-specific antigen values reached statistical difference at 6 mo (median value 2ng/ml vs. 2.4ng/ml; p=0.028).
  • [MeSH-major] Prostatic Hyperplasia / surgery. Transurethral Resection of Prostate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Urol. 2008 Aug;54(2):435-6 [18069122.001]
  • [CommentIn] Eur Urol. 2008 Aug;54(2):436-7 [18069121.001]
  • (PMID = 18069117.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  •  go-up   go-down


91. Morgunov LIu, Vertkin AL, Pushkar' DIu: [Safety of long-term replacement hormonal therapy in patients with erectile dysfunction and androgen deficiency]. Urologiia; 2007 Sep-Oct;(5):49-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Safety of testosterone undecanoate in relation to initiation of cancer and prostatic adenoma (PA) in patients with androgenic deficiency and erectile dysfunction (ED) was studied for 12 months in 49 patients aged 57 to 73 years treated with intramuscular testosteron injections.
  • The size of the prostate in patients with adenoma was 46.34 +/- 21.12 cm3 while in adenoma-free patients--19.11 +/- 6.57 sm3.
  • Thus, long-term therapy with testosterone undecanoate has no effect on PSA level, does not induce urinary obstruction with enlarged prostate.
  • The presence of DM-2 is not a contraindication for androgen therapy in adenoma patients.
  • By reducing body mass index, total cholesterol, triglycerides and LDLP, testosterone therapy lowers the risk of prostatic cancer.
  • [MeSH-minor] Aged. Diabetes Mellitus, Type 2 / complications. Diabetes Mellitus, Type 2 / diagnosis. Humans. Male. Middle Aged. Prostate-Specific Antigen / analysis. Prostatic Hyperplasia / chemically induced. Prostatic Hyperplasia / diagnosis. Prostatic Neoplasms / chemically induced. Prostatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18254226.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Androgens; 3XMK78S47O / Testosterone; EC 3.4.21.77 / Prostate-Specific Antigen; H16A5VCT9C / testosterone undecanoate
  •  go-up   go-down


92. Protogerou V, Argyropoulos V, Patrozos K, Tekerlekis P, Kostakopoulos A: An alternative minimally invasive technique for large prostates (&gt;80 mL): transvesical prostatectomy through a 3-cm incision. Urology; 2010 Jan;75(1):184-6
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 165 patients with benign prostatic hyperplasia were treated with transvesical prostatectomy through a 3-cm incision.
  • Prostate size was 85-144 cm(3) (mean 101 cm(3)).
  • Prostate adenoma was removed with finger dissection without the placement of hemostatic sutures.
  • [MeSH-major] Prostatectomy / methods. Prostatic Hyperplasia / pathology. Prostatic Hyperplasia / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2011 Mar;77(3):768; author reply 768-9 [21377027.001]
  • (PMID = 19896175.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Moslehi R, Chatterjee N, Church TR, Chen J, Yeager M, Weissfeld J, Hein DW, Hayes RB: Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma. Pharmacogenomics; 2006 Sep;7(6):819-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking, N-acetyltransferase genes and the risk of advanced colorectal adenoma.
  • BACKGROUND: Cigarette use is associated with greater risk for colorectal adenoma, a colorectal cancer precursor.
  • METHODS: In the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, we compared NAT1 and NAT2 gene variant distributions for 772 cases with left-sided advanced adenoma and 777 gender and age-matched controls.
  • RESULTS: Risks for advanced colorectal adenoma were significantly increased among recent smokers (current smokers or those who quit less than 10 years ago) (odds ratio [OR] = 2.3, 95% confidence interval [CI]: 1.7-3.1) and among those who smoked more than 20 cigarettes per day (OR = 1.7, 95% CI: 1.3-2.2), compared with nonsmokers.
  • CONCLUSIONS: Our study indicated that NAT2 gene variants associated with a slow acetylator phenotype were more susceptible to the effects of tobacco smoking with respect to adenoma risk, providing leads for disease prevention.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16981843.001).
  • [ISSN] 1462-2416
  • [Journal-full-title] Pharmacogenomics
  • [ISO-abbreviation] Pharmacogenomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-34627; United States / NCI NIH HHS / CA / CA034627-21; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / R01 CA034627; United States / NCI NIH HHS / CA / R01 CA034627-21
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


94. Kunju LP: Nephrogenic adenoma: report of a case and review of morphologic mimics. Arch Pathol Lab Med; 2010 Oct;134(10):1455-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephrogenic adenoma: report of a case and review of morphologic mimics.
  • Nephrogenic adenoma, also referred to as nephrogenic metaplasia, is an uncommon benign lesion of the urothelial tract, characterized by a circumscribed proliferation of tubules, cysts, and papillae lined by cells with low cuboidal to columnar epithelium.
  • The diagnostic features that are useful in the recognition of this benign entity are the characteristic mixture of various architectural patterns, associated stromal edema and inflammation, hyaline sheath around tubules, eosinophilic colloidlike secretion within tubules, and lack of mitotic activity.
  • Nephrogenic adenoma can be a significant diagnostic pitfall as certain histologic features, such as the presence of enlarged nuclei with prominent nucleoli, degenerative nuclear atypia, tiny tubules with blue mucin simulating signet ring cells, and focal invasion into superficial muscle, when taken out of context, can mimic malignancy.
  • Herein, I report a case of nephrogenic adenoma with some worrisome histologic features and review the diagnostic criteria as well as pertinent morphologic malignant mimics of nephrogenic adenoma.
  • [MeSH-major] Adenoma / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Male. Neoplasm Invasiveness. Prostate-Specific Antigen / blood. Sex Ratio. Urethra / pathology. Urothelium / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20923300.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


95. Le Bras M, Borgne-Sanchez A, Touat Z, El Dein OS, Deniaud A, Maillier E, Lecellier G, Rebouillat D, Lemaire C, Kroemer G, Jacotot E, Brenner C: Chemosensitization by knockdown of adenine nucleotide translocase-2. Cancer Res; 2006 Sep 15;66(18):9143-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most importantly, ANT2, but not ANT1, silencing facilitated MMP induction by lonidamine, a mitochondrion-targeted antitumor compound already used in clinical studies for breast, ovarian, glioma, and lung cancer as well as prostate adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982757.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotide Translocator 1; 0 / Adenine Nucleotide Translocator 2; 0 / Antineoplastic Agents; 0 / Indazoles; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 8L70Q75FXE / Adenosine Triphosphate; U78804BIDR / lonidamine
  •  go-up   go-down


96. Pinsky PF, Schoen RE, Weissfeld JL, Church T, Yokochi LA, Doria-Rose VP, Prorok P: The yield of surveillance colonoscopy by adenoma history and time to examination. Clin Gastroenterol Hepatol; 2009 Jan;7(1):86-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The yield of surveillance colonoscopy by adenoma history and time to examination.
  • BACKGROUND & AIMS: Surveillance colonoscopy is recommended for subjects with a history of adenomas but there is limited information on the yield of surveillance.
  • METHODS: A sample of subjects in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial with abnormal flexible sigmoidoscopy and follow-up colonoscopy were queried about subsequent surveillance colonoscopy over a 10-year period.
  • Subjects with advanced adenomas, nonadvanced adenoma, nonadenomatous polyps, and no polyps at baseline were included.
  • RESULTS: At the first surveillance, 10.5% had advanced adenoma and 37% had any adenoma in the advanced adenoma group (n = 1057), compared with rates of 6.8% and 32% (nonadvanced adenoma: n = 765), 4.9% and 22% (nonadenomatous polyps: n = 658), and 3.1% and 16% (no polyps: n = 127) (P < .0001, linear trend test).
  • Mean (SD) time intervals (years) from baseline colonoscopy to first surveillance were 3.4 (2.0) for advanced adenoma, 4.3 (2.0) for nonadvanced adenoma, 4.5 (2.0) for nonadenomatous polyps, and 4.7 (2.0) for no polyps.
  • There were no increasing (or decreasing) trends in the observed rate of advanced adenoma or any adenoma with time to the initial surveillance examination in any baseline group.
  • Among subjects with a second surveillance examination, adenoma findings at both baseline and first surveillance influenced the rates of advanced adenoma and any adenoma at second surveillance.
  • CONCLUSIONS: Subjects with baseline advanced adenomas are more likely to have recurrent advanced adenomas at initial surveillance.
  • The lack of association between recurrence rates and time to surveillance suggests limitations in our understanding of the biology of adenoma development.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonoscopy. Mass Screening / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829395.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


97. Józsa LG: Histologic diagnoses of tissues from two nineteenth century Habsburgs. Paleopathol Newsl; 2008 Mar;(141):12-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gout (urate nephropathy), severe arteriosclerosis, prostate adenoma and purulent prostatitis could also be diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18831390.001).
  • [ISSN] 0148-4737
  • [Journal-full-title] Paleopathology newsletter
  • [ISO-abbreviation] Paleopathol Newsl
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Habsburg J; Romanova AP
  •  go-up   go-down


98. Ali IU, Luke BT, Dean M, Greenwald P: Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma. Br J Cancer; 2005 Oct 17;93(8):953-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allellic variants in regulatory regions of cyclooxygenase-2: association with advanced colorectal adenoma.
  • Cyclooxygenase 2 (Cox-2) is upregulated in colorectal adenomas and carcinomas.
  • In a nested case-control study, four polymorphisms in the Cox-2 gene (two in the promoter, -663 insertion/deletion, GT/(GT) and -798 A/G; one in intron 5-5229, T/G; one in 3'untranslated region (UTR)-8494, T/C) were genotyped in 726 cases of colorectal adenomas and 729 age- and gender-matched controls in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial.
  • There was no significant association between the Cox-2 polymorphisms and adenoma development in the overall population.
  • However, in males, the relatively rare heterozygous genotype GT/(GT) at -663 in the promoter and the variant homozygous genotype G/G at intron 5-5229 appeared to have inverse associations (odds ratio (OR)=0.59, confidence interval (CI): 0.34-1.02 and OR=0.48, CI: 0.24-0.99, respectively), whereas the heterozygous genotype T/C at 3'UTR-8494 had a positive association (OR=1.31, CI: 1.01-1.71) with adenoma development.
  • Furthermore, the haplotype carrying the risk-conferring 3'UTR-8494 variant was associated with a 35% increase in the odds for adenoma incidence in males (OR=1.35, CI: 1.07-1.70), but the one with a risk allele at 3'UTR-8494 and a protective allele at intron 5-5229 had no effect on adenoma development (OR=0.85, CI: 0.66-1.09).
  • Gender-related differences in adenoma risk were also noted with tobacco usage and protective effects of NSAIDs.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 1999 Jan 25;159(2):161-6 [9927099.001]
  • [Cites] Curr Pharm Des. 2004;10(6):635-46 [14965326.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):152-7 [15668489.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9 [15767339.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1293-304 [15753114.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1366-8 [15755763.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 6;97(13):989-97 [15998952.001]
  • [Cites] Mol Cell Biochem. 2000 Jan;203(1-2):41-51 [10724331.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 27;1470(2):M69-78 [10722929.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11750-7 [10766797.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Mol Hum Reprod. 2000 Sep;6(9):771-8 [10956548.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):251S-272S [11189683.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Am J Gastroenterol. 2001 Mar;96(3):882-6 [11280569.001]
  • [Cites] FEBS Lett. 2001 May 11;496(2-3):147-51 [11356200.001]
  • [Cites] JAMA. 2004 May 12;291(18):2221-8 [15138244.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):889-93 [15159324.001]
  • [Cites] Carcinogenesis. 2004 Jun;25(6):961-6 [14754878.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):339-43 [15173859.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):129-35 [2664509.001]
  • [Cites] J Clin Invest. 1991 Jan;87(1):237-46 [1845870.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):105-15 [8461861.001]
  • [Cites] Gynecol Endocrinol. 1993 Dec;7(4):251-8 [8147234.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Surgery. 1998 Aug;124(2):225-31 [9706142.001]
  • [Cites] Oncogene. 2001 Aug 23;20(37):5164-72 [11526505.001]
  • [Cites] J Clin Invest. 2001 Dec;108(11):1657-65 [11733561.001]
  • [Cites] Sci STKE. 2001 Aug 7;2001(94):pe1 [11752669.001]
  • [Cites] J Cell Physiol. 2002 Mar;190(3):279-86 [11857443.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 [12377741.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:95-114 [12432912.001]
  • [Cites] Clin Pharmacol Ther. 2003 Jan;73(1):122-30 [12545150.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):328-36 [12891533.001]
  • [Cites] Nat Rev Genet. 2003 Aug;4(8):626-37 [12897774.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):475-81 [12885872.001]
  • [Cites] Hum Genet. 2003 Oct;113(5):377-81 [12920574.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] Carcinogenesis. 2004 Feb;25(2):229-35 [14604894.001]
  • [Cites] Am J Med. 1999 May;106(5):574-82 [10335731.001]
  • (PMID = 16205694.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01CO12400; United States / NCI NIH HHS / CO / N01-CO-12400; United States / NCI NIH HHS / BC / Z01 BC005652-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS8260; NLM/ PMC1369968
  •  go-up   go-down


99. Neĭmark AI, Isaenko VI, Iakovets IaV, Simashkevich AV, Aliev RT: [Administration of afala preparation in urological practice]. Urologiia; 2009 May-Jun;(3):67-70
MedlinePlus Health Information. consumer health - Urine and Urination.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our studies of afala in patients with prostatic adenoma demonstrate that afala reduces irritative disorders of urination.
  • Afala is indicated for prophylaxis in patients with initial stage of prostatic adenoma and as an alternative to expectation policy.
  • [MeSH-major] Antibodies / therapeutic use. Prostate / drug effects. Prostatic Hyperplasia / drug therapy. Urination Disorders / prevention & control
  • [MeSH-minor] Aged. Drug Administration Schedule. Humans. Male. Middle Aged. Organ Size / drug effects. Prostate-Specific Antigen / blood. Prostate-Specific Antigen / immunology. Quality of Life. Severity of Illness Index. Surveys and Questionnaires. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673125.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies; 0 / afala; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


100. Olgac S, Hutchinson B, Tickoo SK, Reuter VE: Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol; 2006 Feb;19(2):218-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
  • Metanephric adenoma (MA), a well-described renal neoplasm, usually behaves in a benign fashion.
  • Alpha-methylacyl-CoA racemase (AMACR), a molecular marker for prostate carcinoma, has subsequently been found to be overexpressed in breast, colorectal and ovarian cancers, among others.
  • In conclusion, diffuse and strong immunoreactivity for AMACR may be useful in differentiating papillary RCC from MA but a panel which includes AMACR, CK7 and CD57 is better in this differential diagnosis.
  • AMACR is not helpful in differentiating MA from Wilms' tumor, but CD57 is helpful in this differential diagnosis.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Kidney Neoplasms / pathology. Racemases and Epimerases / analysis
  • [MeSH-minor] Antigens, CD57 / analysis. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. WT1 Proteins / analysis. Wilms Tumor / enzymology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424894.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / WT1 Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down






Advertisement